[1m[33m#All pubmed ids: 32709258, 32703911, 32709975, 32726885, 32726822, 32726617, 32726445, 32726432, 32726325, 32725539, 32725451, 32725165, 32724874, 32724790, 32724459, 32724444, 32724428, 32724412, 32724403, 32724397, 32724395, 32724376, 32724363[0m

[1m[31mPubmed ID: 32709258[0m

Title: Catabolism and interactions of uncultured organisms shaped by eco-thermodynamics in methanogenic bioprocesses.

Journal: Microbiome (Microbiome)

Date: 2020-Jul

Abstrct_EN: Current understanding of the carbon cycle in methanogenic environments involves trophic interactions such as interspecies H<sub>2</sub> transfer between organotrophs and methanogens. However, many metabolic processes are thermodynamically sensitive to H<sub>2</sub> accumulation and can be inhibited by H<sub>2</sub> produced from co-occurring metabolisms. Strategies for driving thermodynamically competing metabolisms in methanogenic environments remain unexplored. To uncover how anaerobes combat this H<sub>2</sub> conflict in situ, we employ metagenomics and metatranscriptomics to revisit a model ecosystem that has inspired many foundational discoveries in anaerobic ecology-methanogenic bioreactors. Through analysis of 17 anaerobic digesters, we recovered 1343 high-quality metagenome-assembled genomes and corresponding gene expression profiles for uncultured lineages spanning 66 phyla and reconstructed their metabolic capacities. We discovered that diverse uncultured populations can drive H<sub>2</sub>-sensitive metabolisms through (i) metabolic coupling with concurrent H<sub>2</sub>-tolerant catabolism, (ii) forgoing H<sub>2</sub> generation in favor of interspecies transfer of formate and electrons (cytochrome- and pili-mediated) to avoid thermodynamic conflict, and (iii) integration of low-concentration O<sub>2</sub> metabolism as an ancillary thermodynamics-enhancing electron sink. Archaeal populations support these processes through unique methanogenic metabolisms-highly favorable H<sub>2</sub> oxidation driven by methyl-reducing methanogenesis and tripartite uptake of formate, electrons, and acetate. Integration of omics and eco-thermodynamics revealed overlooked behavior and interactions of uncultured organisms, including coupling favorable and unfavorable metabolisms, shifting from H<sub>2</sub> to formate transfer, respiring low-concentration O<sub>2</sub>, performing direct interspecies electron transfer, and interacting with high H<sub>2</sub>-affinity methanogenesis. These findings shed light on how microorganisms overcome aÂ critical obstacle in methanogenic carbon cycles we had hitherto disregardedÂ and provide foundationalÂ insight into anaerobic microbialÂ ecology. Video Abstract.

Abstrct_CN: ç›®å‰å¯¹äº§ç”²çƒ·ç¯å¢ƒä¸­ç¢³å¾ªç¯çš„è®¤è¯†æ¶‰åŠè¥å…»ç›¸äº’ä½œç”¨ï¼Œä¾‹å¦‚æœ‰æœºè¥å…»ç‰©å’Œäº§ç”²çƒ·èŒä¹‹é—´çš„ç§é—´H <sub> 2 </ sub>è½¬ç§»ã€‚ç„¶è€Œï¼Œè®¸å¤šä»£è°¢è¿‡ç¨‹å¯¹H <sub> 2 </ sub>çš„ç§¯ç´¯æ˜¯çƒ­åŠ›å­¦æ•æ„Ÿçš„ï¼Œå¹¶ä¸”å¯ä»¥è¢«å…±ç”Ÿä»£è°¢äº§ç”Ÿçš„H <sub> 2 </ sub>æŠ‘åˆ¶ã€‚åœ¨äº§ç”²çƒ·ç¯å¢ƒä¸­é©±åŠ¨çƒ­åŠ›å­¦ç«äº‰æ€§ä»£è°¢çš„ç­–ç•¥å°šæœªæ¢ç´¢ã€‚ä¸ºäº†æ­ç¤ºåŒæ°§èŒå¦‚ä½•åŸä½å¯¹æŠ—H <sub> 2 </ sub>å†²çªï¼Œæˆ‘ä»¬é‡‡ç”¨å®åŸºå› ç»„å­¦å’Œè¶…è½¬å½•ç»„å­¦é‡æ–°å®¡è§†äº†ä¸€ä¸ªæ¨¡å‹ç”Ÿæ€ç³»ç»Ÿï¼Œè¯¥æ¨¡å‹ç”Ÿæ€ç³»ç»Ÿå¯å‘äº†åŒæ°§ç”Ÿæ€å­¦-ç”²çƒ·ç”Ÿç‰©ååº”å™¨ä¸­çš„è®¸å¤šåŸºç¡€å‘ç°ã€‚é€šè¿‡å¯¹17ä¸ªåŒæ°§æ¶ˆåŒ–æ± çš„åˆ†æï¼Œæˆ‘ä»¬ä¸ºè·¨è¶Š66ä¸ªé—¨çš„æœªåŸ¹å…»è°±ç³»æ¢å¤äº†1343ä¸ªé«˜è´¨é‡çš„å…ƒåŸºå› ç»„ç»„è£…åŸºå› ç»„å’Œç›¸åº”çš„åŸºå› è¡¨è¾¾è°±ï¼Œå¹¶é‡å»ºäº†å®ƒä»¬çš„ä»£è°¢èƒ½åŠ›ã€‚æˆ‘ä»¬å‘ç°ï¼Œä¸åŒçš„æœªåŸ¹å…»ç§ç¾¤å¯ä»¥é€šè¿‡ï¼ˆiï¼‰ä»£è°¢è€¦åˆä¸åŒæ—¶å‘ç”Ÿçš„H <sub> 2 </ sub>è€å—çš„åˆ†è§£ä»£è°¢æ¥é©±åŠ¨H <sub> 2 </ sub>æ•æ„Ÿçš„ä»£è°¢ï¼Œï¼ˆiiï¼‰æ”¾å¼ƒH <sub> 2 </ sub>çš„äº§ç”Ÿæœ‰åˆ©äºç”²é…¸å’Œç”µå­ä¹‹é—´çš„ç§é—´è½¬ç§»ï¼ˆç»†èƒè‰²ç´ å’ŒèŒæ¯›ä»‹å¯¼ï¼‰ï¼Œä»¥é¿å…çƒ­åŠ›å­¦å†²çªï¼Œä»¥åŠï¼ˆiiiï¼‰å°†ä½æµ“åº¦O <sub> 2 </ sub>ä»£è°¢æ•´åˆä¸ºè¾…åŠ©çƒ­åŠ›å­¦å¢å¼ºç”µå­æ¥æ”¶å™¨ã€‚å¤ç»†èŒç§ç¾¤é€šè¿‡ç‹¬ç‰¹çš„äº§ç”²çƒ·ä»£è°¢æ”¯æŒè¿™äº›è¿‡ç¨‹-é«˜åº¦æœ‰åˆ©çš„H <sub> 2 </ sub>æ°§åŒ–ï¼Œç”±ç”²åŸºè¿˜åŸç”²çƒ·ç”Ÿæˆå’Œç”²é…¸é…¯ï¼Œç”µå­å’Œä¹™é…¸çš„ä¸‰æ–¹å¸æ”¶é©±åŠ¨ã€‚ç»„å­¦å’Œç”Ÿæ€çƒ­åŠ›å­¦çš„æ•´åˆæ­ç¤ºäº†æœªåŸ¹å…»ç”Ÿç‰©çš„è¡Œä¸ºå’Œç›¸äº’ä½œç”¨è¢«å¿½ç•¥äº†ï¼ŒåŒ…æ‹¬è‰¯å¥½å’Œä¸åˆ©çš„æ–°é™ˆä»£è°¢è€¦åˆï¼Œä»H <sub> 2 </ sub>è½¬ç§»åˆ°ç”²é…¸è½¬ç§»ï¼Œå‘¼å¸ä½æµ“åº¦O <sub> 2 </ sub >ï¼Œè¿›è¡Œç›´æ¥çš„ç§é—´ç”µå­è½¬ç§»ï¼Œå¹¶ä¸é«˜H <sub> 2 </ sub>äº²å’Œæ€§ç”²çƒ·åŒ–ç›¸äº’ä½œç”¨ã€‚è¿™äº›å‘ç°æ­ç¤ºäº†å¾®ç”Ÿç‰©å¦‚ä½•å…‹æœè¿„ä»Šä¸ºæ­¢æˆ‘ä»¬æ‰€å¿½ç•¥çš„äº§ç”²çƒ·ç¢³å¾ªç¯ä¸­çš„å…³é”®éšœç¢ï¼Œå¹¶ä¸ºåŒæ°§å¾®ç”Ÿç‰©ç”Ÿæ€å­¦æä¾›äº†åŸºç¡€çŸ¥è¯†ã€‚å½•åƒæ‘˜è¦ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32703911[0m

Title: Can Dietary Fatty Acids Affect the COVID-19 Infection Outcome in Vulnerable Populations?

Journal: mBio (mBio)

Date: 2020-07

Abstrct_EN: There is high mortality in coronavirus disease 2019 (COVID-19)-infected individuals with chronic inflammatory diseases, like obesity, diabetes, and hypertension. A cytokine storm in some patients after infection contributes to this mortality. In addition to lungs, the intestine is targeted during COVID-19 infection. The intestinal membrane serves as a barrier to prevent leakage of microorganisms and their products into the bloodstream; however, dietary fats can affect the gut microbiome and may increase intestinal permeability. In obese or diabetic individuals, there is an increase in the abundance of either Gram-negative bacteria in the gut or their product, endotoxin, in systemic circulation. We speculate that when the COVID-19 infection localizes in the intestine and when the permeability properties of the intestinal membrane are compromised, an inflammatory response is generated when proinflammatory endotoxin, produced by resident Gram-negative bacteria, leaks into the systemic circulation. This review discusses conditions contributing to inflammation that are triggered by microbially derived factors from the gut.

Abstrct_CN: å† çŠ¶ç—…æ¯’ç–¾ç—…2019ï¼ˆCOVID-19ï¼‰æ„ŸæŸ“çš„æ…¢æ€§ç‚ç—‡æ€§ç–¾ç—…ï¼ˆå¦‚è‚¥èƒ–ç—‡ï¼Œç³–å°¿ç—…å’Œé«˜è¡€å‹ï¼‰çš„æ­»äº¡ç‡å¾ˆé«˜ã€‚æ„ŸæŸ“åæŸäº›æ‚£è€…çš„ç»†èƒå› å­é£æš´å¯å¯¼è‡´è¿™ç§æ­»äº¡ã€‚é™¤è‚ºå¤–ï¼Œåœ¨COVID-19æ„ŸæŸ“æœŸé—´è¿˜ä»¥è‚ é“ä¸ºç›®æ ‡ã€‚è‚ è†œæ˜¯é˜²æ­¢å¾®ç”Ÿç‰©åŠå…¶äº§ç‰©æ¸—å…¥è¡€æ¶²çš„å±éšœã€‚ç„¶è€Œï¼Œè†³é£Ÿè„‚è‚ªä¼šå½±å“è‚ é“å¾®ç”Ÿç‰©ç»„ï¼Œå¹¶å¯èƒ½å¢åŠ è‚ é“é€šé€æ€§ã€‚åœ¨è‚¥èƒ–æˆ–ç³–å°¿ç—…ä¸ªä½“ä¸­ï¼Œè‚ é“ä¸­é©å…°æ°é˜´æ€§ç»†èŒæˆ–å…¶äº§ç‰©å†…æ¯’ç´ åœ¨ç³»ç»Ÿå¾ªç¯ä¸­çš„ä¸°åº¦å¢åŠ ã€‚æˆ‘ä»¬æ¨æµ‹ï¼Œå½“COVID-19æ„ŸæŸ“ä½äºè‚ é“å†…ï¼Œå¹¶ä¸”å½“è‚ è†œçš„é€šé€æ€§å—åˆ°æŸå®³æ—¶ï¼Œå½“é©»ç•™çš„é©å…°æ°é˜´æ€§ç»†èŒäº§ç”Ÿçš„ä¿ƒç‚æ€§å†…æ¯’ç´ æ³„æ¼åˆ°ä½“å¾ªç¯ä¸­æ—¶ï¼Œå°±ä¼šäº§ç”Ÿç‚ç—‡ååº”ã€‚è¿™ç¯‡ç»¼è¿°è®¨è®ºäº†ç”±è‚ é“ä¸­å¾®ç”Ÿç‰©è¡ç”Ÿçš„å› ç´ è§¦å‘çš„ä¿ƒå‘ç‚ç—‡çš„ç–¾ç—…ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32709975[0m

Title: Termite mounds contain soil-derived methanotroph communities kinetically adapted to elevated methane concentrations.

Journal: The ISME journal (ISME J)

Date: 2020-Jul

Abstrct_EN: Termite mounds have recently been confirmed to mitigate approximately half of termite methane (CH<sub>4</sub>) emissions, but the aerobic CH<sub>4</sub> oxidising bacteria (methanotrophs) responsible for this consumption have not been resolved. Here, we describe the abundance, composition and CH<sub>4</sub> oxidation kinetics of the methanotroph communities in the mounds of three distinct termite species sampled from Northern Australia. Results from three independent methods employed show that methanotrophs are rare members of microbial communities in termite mounds, with a comparable abundance but distinct composition to those of adjoining soil samples. Across all mounds, the most abundant and prevalent methane monooxygenase sequences were affiliated with upland soil cluster Î± (USCÎ±), with sequences homologous to Methylocystis and tropical upland soil cluster (TUSC) also detected. The reconstruction of a metagenome-assembled genome of a mound USCÎ± representative highlighted the metabolic capabilities of this group of methanotrophs. The apparent Michaelis-Menten kinetics of CH<sub>4</sub> oxidation in mounds were estimated from in situ reaction rates. Methane affinities of the communities were in the low micromolar range, which is one to two orders of magnitude higher than those of upland soils, but significantly lower than those measured in soils with a large CH<sub>4</sub> source such as landfill cover soils. The rate constant of CH<sub>4</sub> oxidation, as well as the porosity of the mound material, were significantly positively correlated with the abundance of methanotroph communities of termite mounds. We conclude that termite-derived CH<sub>4</sub> emissions have selected for distinct methanotroph communities that are kinetically adapted to elevated CH<sub>4</sub> concentrations. However, factors other than substrate concentration appear to limit methanotroph abundance and hence these bacteria only partially mitigate termite-derived CH<sub>4</sub> emissions. Our results also highlight the predominant role of USCÎ± in an environment with elevated CH<sub>4</sub> concentrations and suggest a higher functional diversity within this group than previously recognised.

Abstrct_CN: æœ€è¿‘å·²ç¡®è®¤ç™½èšä¸˜å¯ä»¥å‡è½»å¤§çº¦ä¸€åŠçš„ç™½èšç”²çƒ·ï¼ˆCH <sub> 4 </ sub>ï¼‰æ’æ”¾ï¼Œä½†æ˜¯å°šæœªå¼•èµ·è¿™ç§æ¶ˆè€—çš„å¥½æ°§CH <sub> 4 </ sub>æ°§åŒ–ç»†èŒï¼ˆç”²çƒ·ï¼‰ã€‚è§£å†³ã€‚åœ¨è¿™é‡Œï¼Œæˆ‘ä»¬æè¿°äº†ä»åŒ—æ¾³å¤§åˆ©äºšé‡‡æ ·çš„ä¸‰ç§ä¸åŒç™½èšç‰©ç§çš„åœŸå †ä¸­ç”²çƒ·è¥å…»èŒç¾¤è½çš„ä¸°åº¦ï¼Œç»„æˆå’ŒCH <sub> 4 </ sub>æ°§åŒ–åŠ¨åŠ›å­¦ã€‚ä¸‰ç§ç‹¬ç«‹æ–¹æ³•çš„ç»“æœè¡¨æ˜ï¼Œç”²çƒ·è¥å…»èŒæ˜¯ç™½èšä¸˜ä¸­å¾®ç”Ÿç‰©ç¾¤è½çš„ç¨€æœ‰æˆå‘˜ï¼Œå…¶ä¸°åº¦å¯æ¯”ä½†ä¸ç›¸é‚»åœŸå£¤æ ·å“çš„å¾®ç”Ÿç‰©ç»„æˆæˆªç„¶ä¸åŒã€‚åœ¨æ‰€æœ‰åœŸä¸˜ä¸­ï¼Œæœ€ä¸°å¯Œï¼Œæœ€æ™®éçš„ç”²çƒ·å•åŠ æ°§é…¶åºåˆ—ä¸å±±åœ°åœŸå£¤ç°‡Î±ï¼ˆUSCÎ±ï¼‰ç›¸å…³ï¼Œå¹¶ä¸”ä¸ç”²åŸºå›Šè—»å’Œçƒ­å¸¦å±±åœ°åœŸå£¤ç°‡ï¼ˆTUSCï¼‰åŒæºã€‚åœŸå¢©USCÎ±ä»£è¡¨çš„åŸºå› ç»„ç»„è£…åŸºå› ç»„çš„é‡å»ºçªæ˜¾äº†è¿™ä¸€ç»„ç”²çƒ·è¥å…»ç”Ÿç‰©çš„ä»£è°¢èƒ½åŠ›ã€‚æ ¹æ®åŸä½ååº”é€Ÿç‡ä¼°ç®—äº†CH <sub> 4 </ sub>åœ¨åœŸå †ä¸­çš„è¡¨è§‚Michaelis-MentenåŠ¨åŠ›å­¦ã€‚ç¾¤è½çš„ç”²çƒ·äº²å’ŒåŠ›å¤„äºè¾ƒä½çš„å¾®æ‘©å°”èŒƒå›´ï¼Œæ¯”é™†åœ°åœŸå£¤çš„ç”²çƒ·äº²å’ŒåŠ›é«˜ä¸€åˆ°ä¸¤ä¸ªæ•°é‡çº§ï¼Œä½†æ˜¾ç€ä½äºCH <sub> 4 </ sub>æ¥æºè¾ƒå¤§çš„åœŸå£¤ä¸­çš„ç”²çƒ·äº²å’ŒåŠ›ã€‚åƒåœ¾å¡«åŸ‹åœºè¦†ç›–åœŸå£¤ã€‚ CH <sub> 4 </ sub>çš„æ°§åŒ–é€Ÿç‡å¸¸æ•°ä»¥åŠåœŸå †ææ–™çš„å­”éš™ç‡ä¸ç™½èšåœŸä½“ç”²çƒ·è¥å…»èŒç¾¤è½çš„ä¸°å¯Œç¨‹åº¦å‘ˆæ˜¾ç€æ­£ç›¸å…³ã€‚æˆ‘ä»¬å¾—å‡ºçš„ç»“è®ºæ˜¯ï¼Œç™½èšè¡ç”Ÿçš„CH <sub> 4 </ sub>æ’æ”¾ç‰©å·²è¢«é€‰æ‹©ç”¨äºä¸åŒçš„ç”²çƒ·è¥å…»ç”Ÿç‰©ç¾¤è½ï¼Œè¿™äº›ç¾¤è½åœ¨åŠ¨åŠ›å­¦ä¸Šé€‚åº”äºå‡é«˜çš„CH <sub> 4 </ sub>æµ“åº¦ã€‚ç„¶è€Œï¼Œé™¤åº•ç‰©æµ“åº¦å¤–ï¼Œå…¶ä»–å› ç´ ä¼¼ä¹ä¹Ÿé™åˆ¶äº†ç”²çƒ·æ°§åŒ–èŒçš„ä¸°åº¦ï¼Œå› æ­¤è¿™äº›ç»†èŒåªèƒ½éƒ¨åˆ†å‡è½»ç™½èšè¡ç”Ÿçš„CH <sub> 4 </ sub>çš„æ’æ”¾ã€‚æˆ‘ä»¬çš„ç ”ç©¶ç»“æœè¿˜çªå‡ºæ˜¾ç¤ºäº†USCÎ±åœ¨CH <sub> 4 </ sub>æµ“åº¦å‡é«˜çš„ç¯å¢ƒä¸­çš„ä¸»è¦ä½œç”¨ï¼Œå¹¶è¡¨æ˜è¯¥ç»„ä¸­çš„åŠŸèƒ½å¤šæ ·æ€§æ¯”ä»¥å‰å…¬è®¤çš„æ›´é«˜ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32726885[0m

Title: Diagnostic performances of the Afirma gene sequencing classifier in comparison with the gene expression classifier: A meta-analysis.

Journal: Cancer cytopathology (Cancer Cytopathol)

Date: 2020-Jul

Abstrct_EN: The Afirma microarray-based Gene Expression Classifier (GEC) with its high negative predictive value (NPV) and sensitivity has been used to rule out cancer from thyroid nodules with an indeterminate cytology but not to rule in cancer because of its low positive predictive value (PPV) and specificity. The Gene Sequencing Classifier (GSC) has been reported to improve on the weakness of GEC. In this study, a meta-analysis was performed to compare the clinical impact and diagnostic performance of GEC and GSC. Relevant data were searched in PubMed and Web of Science. Meta-analyses for proportion and dichotomous outcomes were performed to compare the benign call rates (BCRs), resection rates (RRs), risks of malignancy (ROMs), sensitivities, specificities, PPVs, and NPVs of GSC and GEC. Seven studies were included for the meta-analyses. Compared with GEC, GSC had a higher BCR (65.3% vs 43.8%; PÂ <Â .001), a lower RR (26.8% vs 50.1%; PÂ <Â .001), and a higher ROM (60.1% vs 37.6%; PÂ <Â .001). The BCR of HÃ¼rthle cell-predominant nodules was significantly elevated (73.7% vs 21.4%; PÂ <Â .001). In addition, the specificity (43.0% vs 25.1%; PÂ =Â .003) and PPV (63.1% vs 41.6%; PÂ =Â .004) of Afirma GSC were significantly improved while it still maintained a high sensitivity (94.3%) and a high NPV (90.0%). In conclusion, this study confirms and highlighted the clinical and diagnostic significance of GSC. With an increased BCR and improved diagnostic performance, GSC could reduce the rate of unnecessary surgical interventions and better tailor the clinical decisions of patients with indeterminate thyroid fine-needle aspiration results.

Abstrct_CN: åŸºäºAfirmaåŸºå› èŠ¯ç‰‡çš„åŸºå› è¡¨è¾¾åˆ†ç±»å™¨ï¼ˆGECï¼‰å…·æœ‰è¾ƒé«˜çš„é˜´æ€§é¢„æµ‹å€¼ï¼ˆNPVï¼‰å’Œæ•æ„Ÿæ€§ï¼Œå·²è¢«ç”¨äºä»ç»†èƒå­¦ä¸ç¡®å®šçš„ç”²çŠ¶è…ºç»“èŠ‚ä¸­æ’é™¤ç™Œç—‡ï¼Œä½†ç”±äºå…¶é˜³æ€§é¢„æµ‹å€¼è¾ƒä½ï¼Œå› æ­¤æ— æ³•æ’é™¤ç™Œç—‡ï¼ˆ PPVï¼‰å’Œç‰¹å¼‚æ€§ã€‚æ®æŠ¥é“ï¼ŒåŸºå› æµ‹åºåˆ†ç±»å™¨ï¼ˆGSCï¼‰å¯æ”¹å–„GECçš„å¼±ç‚¹ã€‚åœ¨è¿™é¡¹ç ”ç©¶ä¸­ï¼Œè¿›è¡Œäº†èŸèƒåˆ†æï¼Œä»¥æ¯”è¾ƒGECå’ŒGSCçš„ä¸´åºŠå½±å“å’Œè¯Šæ–­æ€§èƒ½ã€‚åœ¨PubMedå’ŒWeb of Scienceä¸­æœç´¢äº†ç›¸å…³æ•°æ®ã€‚è¿›è¡Œäº†æ¯”ä¾‹å’ŒäºŒåˆ†ç»“æœçš„èŸèƒåˆ†æï¼Œä»¥æ¯”è¾ƒGSCå’ŒGECçš„è‰¯æ€§æ£€å‡ºç‡ï¼ˆBCRï¼‰ï¼Œåˆ‡é™¤ç‡ï¼ˆRRï¼‰ï¼Œæ¶æ€§é£é™©ï¼ˆROMï¼‰ï¼Œæ•æ„Ÿæ€§ï¼Œç‰¹å¼‚æ€§ï¼ŒPPVå’ŒNPVã€‚èŸèƒåˆ†æåŒ…æ‹¬ä¸ƒé¡¹ç ”ç©¶ã€‚ä¸GECç›¸æ¯”ï¼ŒGSCçš„BCRè¾ƒé«˜ï¼ˆ65.3ï¼…vs 43.8ï¼…; P <.001ï¼‰ï¼ŒRRè¾ƒä½ï¼ˆ26.8ï¼…vs 50.1ï¼…; P <.001ï¼‰ï¼ŒROMè¾ƒé«˜ï¼ˆ60.1ï¼…vs 37.6ï¼…; P <.001ï¼‰ã€‚ HÃ¼rthleç»†èƒä¸ºä¸»çš„ç»“èŠ‚çš„BCRæ˜¾ç€å‡é«˜ï¼ˆ73.7ï¼…vs 21.4ï¼…; P <.001ï¼‰ã€‚æ­¤å¤–ï¼ŒAfirma GSCçš„ç‰¹å¼‚æ€§ï¼ˆ43.0ï¼…vs 25.1ï¼…; P = .003ï¼‰å’ŒPPVï¼ˆ63.1ï¼…vs 41.6ï¼…; P = .004ï¼‰æ˜¾ç€æé«˜ï¼ŒåŒæ—¶ä»ä¿æŒé«˜çµæ•åº¦ï¼ˆ94.3ï¼…ï¼‰å’Œé«˜å‡€ç°å€¼ï¼ˆ90.0ï¼…ï¼‰ã€‚æ€»ä¹‹ï¼Œè¿™é¡¹ç ”ç©¶è¯å®å¹¶å¼ºè°ƒäº†GSCçš„ä¸´åºŠå’Œè¯Šæ–­æ„ä¹‰ã€‚éšç€BCRçš„å¢åŠ å’Œè¯Šæ–­æ€§èƒ½çš„æé«˜ï¼ŒGSCå¯ä»¥å‡å°‘ä¸å¿…è¦çš„å¤–ç§‘æ‰‹æœ¯å¹²é¢„çš„æ¯”ç‡ï¼Œå¹¶æ›´å¥½åœ°è°ƒæ•´ä¸ç¡®å®šçš„ç”²çŠ¶è…ºç»†é’ˆç©¿åˆºç»“æœæ‚£è€…çš„ä¸´åºŠå†³ç­–ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32726822[0m

Title: Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future.

Journal: Hamostaseologie (Hamostaseologie)

Date: 2020-Aug

Abstrct_EN: A strong link between cancer and thrombosis has been well recognized. The occurrence of venous thromboembolism (VTE) can be the first clinical sign of an undiagnosed (i.e., occult) cancer. Cancer is more often diagnosed after unprovoked compared with provoked VTE events, with a reported risk in recent studies of around 5%. Extensive, imaging-based screening strategies to detect occult cancer after unprovoked VTE do not appear to have a clear clinical benefit compared with a more limited cancer screening. To identify patients with unprovoked VTE at high risk of occult cancer, risk factors have been explored and prediction models developed. Relevant risk factors for occult cancer include male sex, age, anemia, chronic lung disease, and thrombocytosis. Studies with preselection of patients based on risk assessment and evaluation of limited versus extensive screening strategies are currently ongoing. Also, novel and promising approaches for early detection of cancer in patients with unprovoked VTE by means of liquid biopsies, which include analysis of circulating tumor cells, cell-free tumor DNA, proteomics, or platelet mRNA sequencing, are currently under investigation. In this review, we provide an overview of the risk of cancer diagnosis after VTE, discuss the studies which investigated different screening strategies for occult cancer, summarize risk factors and risk scoring models for identification of patients at high risk of cancer diagnosis after VTE, and highlight ongoing research to optimize screening and identification of patients at risk of occult cancer, which will shape the future clinical practice.

Abstrct_CN: ç™Œç—‡ä¸è¡€æ “å½¢æˆä¹‹é—´çš„ç´§å¯†è”ç³»å·²å¾—åˆ°å…¬è®¤ã€‚é™è„‰è¡€æ “æ “å¡ç—‡ï¼ˆVTEï¼‰çš„å‘ç”Ÿå¯èƒ½æ˜¯æœªè¯Šæ–­ï¼ˆå³éšåŒ¿æ€§ï¼‰ç™Œç—‡çš„ç¬¬ä¸€ä¸ªä¸´åºŠä½“å¾ã€‚ä¸æ¿€èµ·çš„VTEäº‹ä»¶ç›¸æ¯”ï¼Œæœªç»æ¿€æ€’åæ›´å®¹æ˜“è¯Šæ–­å‡ºç™Œç—‡ï¼Œæ®æœ€è¿‘çš„ç ”ç©¶æŠ¥é“ï¼Œè¿™ä¸€é£é™©çº¦ä¸º5ï¼…ã€‚ä¸æ›´æœ‰é™çš„ç™Œç—‡ç­›æŸ¥ç›¸æ¯”ï¼ŒåŸºäºå½±åƒå­¦çš„å¹¿æ³›ç­›æŸ¥ç­–ç•¥åœ¨æ— ç¼˜æ— æ•…çš„VTEåæ£€æµ‹éšåŒ¿æ€§ç™Œç—‡ä¼¼ä¹æ²¡æœ‰æ˜æ˜¾çš„ä¸´åºŠç›Šå¤„ã€‚ä¸ºäº†ç¡®å®šå…·æœ‰éšåŒ¿æ€§ç™Œç—‡é«˜é£é™©çš„æœªç»è¯å®çš„VTEæ‚£è€…ï¼Œå·²ç»æ¢ç´¢äº†å±é™©å› ç´ å¹¶å»ºç«‹äº†é¢„æµ‹æ¨¡å‹ã€‚éšåŒ¿æ€§ç™Œç—‡çš„ç›¸å…³å±é™©å› ç´ åŒ…æ‹¬ç”·æ€§ï¼Œå¹´é¾„ï¼Œè´«è¡€ï¼Œæ…¢æ€§è‚ºç—…å’Œè¡€å°æ¿å¢å¤šç—‡ã€‚ç›®å‰æ­£åœ¨è¿›è¡ŒåŸºäºé£é™©è¯„ä¼°å’Œæœ‰é™ç­›æŸ¥ä¸å¹¿æ³›ç­›æŸ¥ç­–ç•¥è¯„ä¼°çš„æ‚£è€…é¢„é€‰ç ”ç©¶ã€‚å¦å¤–ï¼Œç›®å‰æ­£åœ¨ç ”ç©¶é€šè¿‡æ¶²ä½“æ´»æ£€æ—©æœŸæ£€æµ‹æœªç»æ²»ç–—çš„VTEæ‚£è€…çš„ç™Œç—‡çš„æ–°é¢–ä¸”æœ‰å¸Œæœ›çš„æ–¹æ³•ï¼ŒåŒ…æ‹¬åˆ†æå¾ªç¯è‚¿ç˜¤ç»†èƒï¼Œæ— ç»†èƒè‚¿ç˜¤DNAï¼Œè›‹ç™½è´¨ç»„å­¦æˆ–è¡€å°æ¿mRNAæµ‹åºã€‚åœ¨è¿™ç¯‡ç»¼è¿°ä¸­ï¼Œæˆ‘ä»¬æ¦‚è¿°äº†VTEåçš„ç™Œç—‡è¯Šæ–­é£é™©ï¼Œè®¨è®ºäº†ç ”ç©¶é’ˆå¯¹éšåŒ¿æ€§ç™Œç—‡çš„ä¸åŒç­›æŸ¥ç­–ç•¥çš„ç ”ç©¶ï¼Œæ€»ç»“äº†é£é™©å› ç´ å’Œé£é™©è¯„åˆ†æ¨¡å‹ï¼Œä»¥é‰´å®šVTEåå¤„äºé«˜ç™Œç—‡è¯Šæ–­é£é™©çš„æ‚£è€…ï¼Œä»¥åŠé‡ç‚¹ä»‹ç»æ­£åœ¨è¿›è¡Œçš„ç ”ç©¶ï¼Œä»¥ä¼˜åŒ–å¯¹æ½œä¼æ€§ç™Œç—‡æ‚£è€…çš„ç­›æŸ¥å’Œé‰´å®šï¼Œè¿™å°†å½±å“æœªæ¥çš„ä¸´åºŠå®è·µã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32726617[0m

Title: Cycling Stem Cells Are Radioresistant and Regenerate the Intestine.

Journal: Cell reports (Cell Rep)

Date: 2020-Jul

Abstrct_EN: A certain number of epithelial cells in intestinal crypts are DNA damage resistant and contribute to regeneration. However, the cellular mechanism underlying intestinal regeneration remains unclear. Using lineage tracing, we show that cells marked by an Msi1 reporter (Msi1<sup>+</sup>) are right above Lgr5<sup>high</sup> cells in intestinal crypts and exhibit DNA damage resistance. Single-cell RNA sequencing reveals that the Msi1<sup>+</sup> cells are heterogeneous with the majority being intestinal stem cells (ISCs). The DNA damage-resistant subpopulation of Msi1<sup>+</sup> cells is characterized by low-to-negative Lgr5 expression and is more rapidly cycling than Lgr5<sup>high</sup> radiosensitive crypt base columnar stem cells (CBCs). This enables an efficient repopulation of the intestinal epithelium at early stage when Lgr5<sup>high</sup> cells are not emerging. Furthermore, relative to CBCs, Msi1<sup>+</sup> cells preferentially produce Paneth cells during homeostasis and upon radiation repair. Together, we demonstrate that the DNA damage-resistant Msi1<sup>+</sup> cells are cycling ISCs that maintain and regenerate the intestinal epithelium.

Abstrct_CN: è‚ éšçªä¸­çš„ä¸€å®šæ•°é‡çš„ä¸Šçš®ç»†èƒå…·æœ‰æŠ—DNAæŸä¼¤ä½œç”¨ï¼Œå¹¶æœ‰åŠ©äºå†ç”Ÿã€‚ç„¶è€Œï¼Œè‚ å†ç”Ÿçš„ç»†èƒæœºåˆ¶ä»ä¸æ¸…æ¥šã€‚ä½¿ç”¨è°±ç³»è¿½è¸ªï¼Œæˆ‘ä»¬å‘ç°ç”±Msi1æŠ¥å‘ŠåŸºå› ï¼ˆMsi1 <sup> + </ sup>ï¼‰æ ‡è®°çš„ç»†èƒåœ¨è‚ é“éšçªä¸­çš„Lgr5 <sup> high </ sup>ç»†èƒæ­£ä¸Šæ–¹ï¼Œå¹¶ä¸”è¡¨ç°å‡ºå¯¹DNAçš„æŠµæŠ—åŠ›ã€‚å•ç»†èƒRNAæµ‹åºæ˜¾ç¤ºMsi1 <sup> + </ sup>ç»†èƒæ˜¯å¼‚è´¨çš„ï¼Œå¤§å¤šæ•°æ˜¯è‚ é“å¹²ç»†èƒï¼ˆISCï¼‰ã€‚ Msi1 <sup> + </ sup>ç»†èƒçš„è€DNAæŸä¼¤äºšç¾¤çš„ç‰¹å¾æ˜¯ä½è‡³è´ŸLgr5è¡¨è¾¾ï¼Œå¹¶ä¸”æ¯”Lgr5 <sup>é«˜</ sup>æ”¾å°„æ•æ„Ÿæ€§éšçªåŸºç¡€æŸ±çŠ¶å¹²ç»†èƒï¼ˆCBCsï¼‰å¾ªç¯æ›´å¿«ï¼‰ã€‚å½“Lgr5 <sup> high </ sup>ç»†èƒæ²¡æœ‰å‡ºç°æ—¶ï¼Œè¿™å¯ä»¥åœ¨æ—©æœŸé˜¶æ®µæœ‰æ•ˆåœ°è¡¥å……è‚ é“ä¸Šçš®ã€‚æ­¤å¤–ï¼Œç›¸å¯¹äºCBCï¼ŒMsi1 <sup> + </ sup>ç»†èƒåœ¨ç¨³æ€å’Œæ”¾å°„ä¿®å¤åä¼˜å…ˆäº§ç”ŸPanethç»†èƒã€‚åœ¨ä¸€èµ·ï¼Œæˆ‘ä»¬è¯æ˜è€DNAæŸä¼¤çš„Msi1 <sup> + </ sup>ç»†èƒæ˜¯ç»´æŒå’Œå†ç”Ÿè‚ ä¸Šçš®çš„å¾ªç¯ISCã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32726445[0m

Title: Association between Vaginal Bacterial Microbiota and Vaginal Yeast Colonization.

Journal: The Journal of infectious diseases (J. Infect. Dis.)

Date: 2020-Jul

Abstrct_EN: Vaginal yeast is frequently found with Lactobacillus-dominant microbiota. The relationship between vaginal yeast and other bacteria has not been well characterized. These analyses utilized data from the Preventing Vaginal Infections trial. Relative abundance of vaginal bacteria from 16S rRNA gene amplicon sequencing and quantities of 10 vaginal bacteria using taxon-directed PCR assays were compared at visits with and without detection of yeast on microscopy, culture, or both. Higher relative abundances of Megasphaera species type 1 (RR 0.70, 95%CI 0.52-0.95), Megasphaera species type 2 (RR 0.81, 95%CI 0.67-0.98) and Mageeibacillus indolicus (RR 0.46, 95%CI 0.25-0.83), were associated with lower risk of detecting yeast. Conversely, higher relative abundances of Bifidobacterium bifidum, Aerococcus christensenii, Lactobacillus mucosae, Streptococcus equinus/infantarius/lutentiensis, Prevotella bivia, Dialister propionicifaciens, and Lactobacillus crispatus/helveticus were associated with yeast detection. Taxon-directed assays confirmed that increasing quantities of both Megasphaera species and M. indolicus were associated with lower risk of detecting yeast while, increasing quantities of L. crispatus were associated with higher risk of detecting yeast. Despite an analysis that examined associations between multiple vaginal bacteria and the presence of yeast, only a small number of vaginal bacteria were strongly and significantly associated with the presence or absence of yeast.

Abstrct_CN: é˜´é“é…µæ¯ç»å¸¸å‘ç°æœ‰ä»¥ä¹³æ†èŒä¸ºä¸»çš„èŒç¾¤ã€‚é˜´é“é…µæ¯èŒä¸å…¶ä»–ç»†èŒä¹‹é—´çš„å…³ç³»å°šæœªå¾—åˆ°å¾ˆå¥½çš„è¡¨å¾ã€‚è¿™äº›åˆ†æåˆ©ç”¨äº†é¢„é˜²é˜´é“æ„ŸæŸ“è¯•éªŒçš„æ•°æ®ã€‚åœ¨è¿›è¡Œæ˜¾å¾®é•œæ£€æŸ¥å’Œ/æˆ–åœ¨æ˜¾å¾®é•œä¸‹æ£€æµ‹æˆ–æœªæ£€æµ‹åˆ°é…µæ¯çš„æƒ…å†µä¸‹ï¼Œåœ¨è®¿é—®å’Œä¸è¿›è¡Œé…µæ¯æ£€æµ‹çš„æƒ…å†µä¸‹ï¼Œå¯¹æ¥è‡ª16S rRNAåŸºå› æ‰©å¢å­æµ‹åºçš„é˜´é“ç»†èŒçš„ç›¸å¯¹ä¸°åº¦å’Œä½¿ç”¨åˆ†ç±»ç¾¤å®šå‘PCRæ£€æµ‹çš„10ç§é˜´é“ç»†èŒçš„æ•°é‡è¿›è¡Œäº†æ¯”è¾ƒã€‚ 1å‹å¤§çƒè—»ï¼ˆRR 0.70ï¼Œ95ï¼…CI 0.52-0.95ï¼‰ï¼Œ2å‹å¤§çƒè—»ï¼ˆRR 0.81ï¼Œ95ï¼…CI 0.67-0.98ï¼‰å’Œé›è“æ†èŒï¼ˆMageeibacillus indolicusï¼‰ï¼ˆRR 0.46ï¼Œ95ï¼…CI 0.25-0.83ï¼‰çš„ç›¸å¯¹ä¸°åº¦è¾ƒé«˜ï¼Œè¢«å‘ç°é…µæ¯çš„é£é™©è¾ƒä½ã€‚ç›¸åï¼ŒåŒæ­§åŒæ­§æ†èŒï¼Œå…‹é‡Œæ–¯æ»•æ£®æ°”å•çƒèŒï¼Œç²˜è†œä¹³æ†èŒï¼Œé©¬é“¾çƒèŒ/ infantarius / lutentiensisï¼ŒBivoä¸™é…¸æ†èŒï¼ŒDialisterä¸™é…¸æ†èŒå’Œcrispisteruscrispatus / helveticusçš„ç›¸å¯¹ä¸°åº¦ä¸é…µæ¯æ£€æµ‹ç›¸å…³ã€‚ä»¥åˆ†ç±»ç¾¤ä¸ºå¯¼å‘çš„æµ‹å®šæ³•è¯å®ï¼Œéº¦åŠ æ°çƒèŒå’Œé›è“å¿µç èŒæ•°é‡çš„å¢åŠ ä¸æ£€æµ‹é…µæ¯èŒçš„é£é™©è¾ƒä½æœ‰å…³ï¼Œè€Œæ¾é¦™ä¹³é…¸èŒçš„å¢åŠ ä¸æ£€æµ‹é…µæ¯èŒçš„é£é™©è¾ƒé«˜æœ‰å…³ã€‚å°½ç®¡æœ‰ä¸€é¡¹åˆ†ææ£€æŸ¥äº†å¤šç§é˜´é“ç»†èŒä¸é…µæ¯èŒä¹‹é—´çš„å…³è”ï¼Œä½†åªæœ‰å°‘æ•°é˜´é“ç»†èŒä¸é…µæ¯èŒçš„å­˜åœ¨ä¸å¦å¯†åˆ‡ç›¸å…³ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32726432[0m

Title: Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.

Journal: Journal of the National Cancer Institute (J. Natl. Cancer Inst.)

Date: 2020-Jul

Abstrct_EN: Radiation therapy is one of the most commonly used cancer therapeutics, but genetic determinants of clinical benefit are poorly characterized. Pathogenic germline variants in ATM are known to cause ataxia-telangiectasia, a rare hereditary syndrome notable for marked radiosensitivity. In contrast, somatic inactivation of ATM is a common event in a wide variety of cancers, but its clinical actionability remains obscure. We analyzed 20,107 consecutively treated advanced cancer patients who underwent targeted genomic sequencing as part of an institutional genomic profiling initiative and identified 1,085 harboring a somatic or germline ATM mutation, including 357 who received radiotherapy. Outcomes of irradiated tumors harboring ATM loss-of-function (LoF) mutations were compared to those harboring variants of unknown significance (VUS). All statistical tests were two-sided. Among 357 pan-cancer patients who received 727 courses of radiotherapy, genetic inactivation of ATM was associated with improved radiotherapeutic efficacy. The 2-year cumulative incidence of irradiated tumor progression was 13.2% vs 27.5% for tumors harboring an ATM LoF vs VUS allele, respectively (HR: 0.51, 95% CIâ€‰=â€‰0.34-0.77, p= .001). The greatest clinical benefit was seen in tumors harboring bi-allelic ATM inactivation (HRâ€‰=â€‰0.19, 95% CIâ€‰=â€‰0.06-0.60, p=.005), with statistically significant benefit also observed in tumors with mono-allelic ATM inactivation (HRâ€‰=â€‰0.57, 95% CIâ€‰=â€‰0.35-0.92, p=.02). Notably, ATM LoF was highly predictive of outcome in TP53 wild type tumors, but not among TP53-mutant tumors. We demonstrate that somatic ATM inactivation is associated with markedly improved tumor control following radiotherapy. The identification of a radiosensitive tumor phenotype across multiple cancer types offers potential clinical opportunities for genomically-guided radiotherapy.

Abstrct_CN: æ”¾å°„ç–—æ³•æ˜¯æœ€å¸¸ç”¨çš„ç™Œç—‡ç–—æ³•ä¹‹ä¸€ï¼Œä½†æ˜¯ä¸´åºŠè·ç›Šçš„é—ä¼ å†³å®šå› ç´ çš„ç‰¹å¾å´å¾ˆå·®ã€‚å·²çŸ¥ATMä¸­çš„è‡´ç—…ç§ç³»å˜å¼‚ä½“ä¼šå¯¼è‡´å…±æµå¤±è°ƒ-æ¯›ç»†è¡€ç®¡æ‰©å¼ ï¼Œè¿™æ˜¯ä¸€ç§ç½•è§çš„é—ä¼ ç»¼åˆå¾ï¼Œä»¥æ˜¾ç€çš„æ”¾å°„æ•æ„Ÿæ€§ä¸ºç‰¹å¾ã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼ŒATMçš„ä½“ç»†èƒå¤±æ´»æ˜¯å¤šç§ç™Œç—‡ä¸­çš„å¸¸è§äº‹ä»¶ï¼Œä½†å…¶ä¸´åºŠå¯æ“ä½œæ€§ä»ç„¶ä¸æ¸…æ¥šã€‚æˆ‘ä»¬åˆ†æäº†20107ä¾‹ç»è¿‡è¿ç»­æ²»ç–—çš„æ™šæœŸç™Œç—‡æ‚£è€…ï¼Œè¿™äº›æ‚£è€…æ¥å—äº†é’ˆå¯¹æ€§çš„åŸºå› ç»„æµ‹åºï¼Œè¿™æ˜¯æœºæ„æ€§åŸºå› ç»„åˆ†æè®¡åˆ’çš„ä¸€éƒ¨åˆ†ï¼Œç¡®å®šäº†1,085ä¾‹å…·æœ‰ä½“ç»†èƒæˆ–ç§ç³»ATMçªå˜çš„æ‚£è€…ï¼Œå…¶ä¸­357ä¾‹æ¥å—äº†æ”¾å°„æ²»ç–—ã€‚å°†æºå¸¦ATMåŠŸèƒ½ä¸§å¤±ï¼ˆLoFï¼‰çªå˜çš„æ”¾å°„è‚¿ç˜¤çš„ç»“æœä¸æºå¸¦æœªçŸ¥é‡è¦æ€§å˜ä½“ï¼ˆVUSï¼‰çš„ç»“æœè¿›è¡Œæ¯”è¾ƒã€‚æ‰€æœ‰ç»Ÿè®¡æ£€éªŒéƒ½æ˜¯åŒé¢çš„ã€‚åœ¨æ¥å—727ç–—ç¨‹æ”¾å°„æ²»ç–—çš„357åå…¨ç™Œæ‚£è€…ä¸­ï¼ŒATMçš„åŸºå› å¤±æ´»ä¸æ”¾ç–—ç–—æ•ˆæé«˜ç›¸å…³ã€‚ 2å¹´ç´¯ç§¯çš„æ”¾ç–—è‚¿ç˜¤è¿›å±•ç´¯ç§¯å‘ç”Ÿç‡åˆ†åˆ«ä¸º13.2ï¼…å’Œ27.5ï¼…ï¼Œè€Œåˆ†åˆ«æºå¸¦ATM LoFå’ŒVUSç­‰ä½åŸºå› çš„æ‚£è€…ï¼ˆHRï¼š0.51ï¼Œ95ï¼…CI = 0.34-0.77ï¼Œp = 0.001ï¼‰ã€‚åœ¨å…·æœ‰åŒç­‰ä½åŸºå› ATMå¤±æ´»çš„è‚¿ç˜¤ä¸­è§‚å¯Ÿåˆ°æœ€å¤§çš„ä¸´åºŠè·ç›Šï¼ˆHR = 0.19ï¼Œ95ï¼…CI = 0.06-0.60ï¼Œp = .005ï¼‰ï¼Œå•ç­‰ä½åŸºå› ATMå¤±æ´»çš„è‚¿ç˜¤ï¼ˆHR = 0.57ï¼Œ95ï¼…CI ï¼ 0.35-0.92ï¼Œp ï¼ 0.02ï¼‰ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒATM LoFå¯ä»¥é«˜åº¦é¢„æµ‹TP53é‡ç”Ÿå‹è‚¿ç˜¤çš„é¢„åï¼Œä½†ä¸èƒ½é¢„æµ‹TP53çªå˜å‹è‚¿ç˜¤çš„é¢„åã€‚æˆ‘ä»¬è¯æ˜äº†ä½“ç»†èƒATMå¤±æ´»ä¸æ”¾ç–—åè‚¿ç˜¤æ§åˆ¶æ˜æ˜¾æ”¹å–„æœ‰å…³ã€‚è·¨å¤šç§ç™Œç—‡ç±»å‹çš„æ”¾å°„æ•æ„Ÿæ€§è‚¿ç˜¤è¡¨å‹çš„é‰´å®šä¸ºåŸºå› ç»„æŒ‡å¯¼çš„æ”¾å°„æ²»ç–—æä¾›äº†æ½œåœ¨çš„ä¸´åºŠæœºä¼šã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32726325[0m

Title: Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2.

Journal: PloS one (PLoS ONE)

Date: No article date

Abstrct_EN: Development of novel approaches for regulating the expression of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) is becoming increasingly important within the context of the ongoing COVID-19 pandemic since these enzymes play a crucial role in cell infection. In this work we searched for putative ACE2 and TMPRSS2 expression regulation networks mediated by various miRNA isoforms (isomiR) across different human organs using publicly available paired miRNA/mRNA-sequencing data from The Cancer Genome Atlas (TCGA) project. As a result, we identified several miRNA families targeting ACE2 and TMPRSS2 genes in multiple tissues. In particular, we found that lysine-specific demethylase 5B (JARID1B), encoded by the KDM5B gene, can indirectly affect ACE2 / TMPRSS2 expression by repressing transcription of hsa-let-7e / hsa-mir-125a and hsa-mir-141 / hsa-miR-200 miRNA families which are targeting these genes.

Abstrct_CN: åœ¨æ­£åœ¨è¿›è¡Œçš„COVID-19å¤§æµè¡Œçš„èƒŒæ™¯ä¸‹ï¼Œè°ƒèŠ‚è¡€ç®¡ç´§å¼ ç´ è½¬åŒ–é…¶2ï¼ˆACE2ï¼‰å’Œè·¨è†œä¸æ°¨é…¸è›‹ç™½é…¶2ï¼ˆTMPRSS2ï¼‰è¡¨è¾¾çš„æ–°æ–¹æ³•çš„å¼€å‘å˜å¾—è¶Šæ¥è¶Šé‡è¦ï¼Œå› ä¸ºè¿™äº›é…¶åœ¨ç»†èƒæ„ŸæŸ“ä¸­èµ·ç€è‡³å…³é‡è¦çš„ä½œç”¨ã€‚åœ¨è¿™é¡¹å·¥ä½œä¸­ï¼Œæˆ‘ä»¬ä½¿ç”¨äº†æ¥è‡ªç™Œç—‡åŸºå› ç»„å›¾è°±ï¼ˆTCGAï¼‰é¡¹ç›®çš„å…¬å¼€é…å¯¹çš„miRNA / mRNAæµ‹åºæ•°æ®ï¼Œæœç´¢äº†è·¨è¶Šä¸åŒäººä½“å™¨å®˜çš„å„ç§miRNAäºšå‹ï¼ˆisomiRï¼‰ä»‹å¯¼çš„å‡å®šçš„ACE2å’ŒTMPRSS2è¡¨è¾¾è°ƒæ§ç½‘ç»œã€‚ç»“æœï¼Œæˆ‘ä»¬åœ¨å¤šä¸ªç»„ç»‡ä¸­é‰´å®šäº†é¶å‘ACE2å’ŒTMPRSS2åŸºå› çš„å‡ ä¸ªmiRNAå®¶æ—ã€‚ç‰¹åˆ«æ˜¯ï¼Œæˆ‘ä»¬å‘ç°ç”±KDM5BåŸºå› ç¼–ç çš„èµ–æ°¨é…¸ç‰¹å¼‚æ€§è„±ç”²åŸºé…¶5Bï¼ˆJARID1Bï¼‰å¯ä»¥é€šè¿‡æŠ‘åˆ¶hsa-let-7e / hsa-mir-125aå’Œhsa-mir-141 /çš„è½¬å½•è€Œé—´æ¥å½±å“ACE2 / TMPRSS2çš„è¡¨è¾¾ã€‚é’ˆå¯¹è¿™äº›åŸºå› çš„hsa-miR-200 miRNAå®¶æ—ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32725539[0m

Title: Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer.

Journal: Drugs - real world outcomes (Drugs Real World Outcomes)

Date: 2020-Jul

Abstrct_EN: Data are sparse concerning the sequential use of multiple anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This study investigated sequencing and outcomes among patients receiving multiple ALK inhibitors. This was a retrospective observational cohort study of adult patients with ALK-positive NSCLC treated with available first- and second-generation ALK inhibitors from 1 September 2011 to 31 December 2017. Duration of therapy (DOT) and overall survival (OS) were assessed with the Kaplan-Meier method. A multivariable linear regression analysis was performed to assess if DOT with a preceding ALK inhibitor was predictive of DOT for subsequent ALK inhibitor treatments. A total of 410 patients were analyzed: 57% received 1 ALK inhibitor; 35%, 2 ALK inhibitors; and 8%, 3-4 ALK inhibitors. Among those receivingâ€‰>â€‰1 ALK inhibitor (nâ€‰=â€‰177), 60% received a crizotinib-led sequence and 39% an alectinib-led sequence. Nearly 60% of the overall population received chemotherapy prior to their first ALK inhibitor. Median OS for the study population was 28Â months, 15Â months in patients who received 1 ALK inhibitor, 42Â months in patients who received 2 ALK inhibitors, and 56Â months in patients who received 3-4 ALK inhibitors. Longer DOT of the first ALK inhibitor was associated with increased DOT of the second (pâ€‰<â€‰0.0001), and longer DOT of the second ALK inhibitor was associated with increased DOT of the third (pâ€‰<â€‰0.0001). This study provides initial information on real-world treatment patterns following the introduction of new ALK inhibitors, and supports the use of sequential ALK therapies.

Abstrct_CN: å…³äºALKé˜³æ€§å±€éƒ¨æ™šæœŸæˆ–è½¬ç§»æ€§éå°ç»†èƒè‚ºç™Œï¼ˆNSCLCï¼‰è¿ç»­ä½¿ç”¨å¤šç§é—´å˜æ€§æ·‹å·´ç˜¤æ¿€é…¶ï¼ˆALKï¼‰æŠ‘åˆ¶å‰‚çš„æ•°æ®å¾ˆå°‘ã€‚è¿™é¡¹ç ”ç©¶è°ƒæŸ¥äº†æ¥å—å¤šç§ALKæŠ‘åˆ¶å‰‚çš„æ‚£è€…çš„æµ‹åºå’Œé¢„åã€‚è¿™æ˜¯ä¸€é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œç ”ç©¶å¯¹è±¡ä¸º2011å¹´9æœˆ1æ—¥è‡³2017å¹´12æœˆ31æ—¥æ¥å—ç¬¬ä¸€ä»£å’Œç¬¬äºŒä»£ALKæŠ‘åˆ¶å‰‚æ²»ç–—çš„ALKé˜³æ€§NSCLCæˆå¹´æ‚£è€…ã€‚é‡‡ç”¨ä»¥ä¸‹æ–¹æ³•è¯„ä¼°æ²»ç–—æ—¶é—´ï¼ˆDOTï¼‰å’Œæ€»ç”Ÿå­˜æœŸï¼ˆOSï¼‰ï¼š Kaplan-Meieræ–¹æ³•ã€‚è¿›è¡Œäº†å¤šå˜é‡çº¿æ€§å›å½’åˆ†æï¼Œä»¥è¯„ä¼°ä½¿ç”¨å…ˆå‰ALKæŠ‘åˆ¶å‰‚çš„DOTæ˜¯å¦å¯é¢„æµ‹éšåALKæŠ‘åˆ¶å‰‚æ²»ç–—çš„DOTã€‚æ€»å…±å¯¹410ä½æ‚£è€…è¿›è¡Œäº†åˆ†æï¼š57ï¼…çš„æ‚£è€…æ¥å—äº†1ç§ALKæŠ‘åˆ¶å‰‚ï¼› 35ï¼…ï¼Œ2ç§ALKæŠ‘åˆ¶å‰‚;å’Œ8ï¼…çš„3-4ç§ALKæŠ‘åˆ¶å‰‚ã€‚åœ¨é‚£äº›æ¥å—ï¼ï¼ 1ä¸ªALKæŠ‘åˆ¶å‰‚çš„æ‚£è€…ä¸­ï¼ˆn ï¼ï¼ 177ï¼‰ï¼Œ60ï¼…æ¥å—äº†å…‹å”‘æ›¿å°¼å¼•å¯¼çš„åºåˆ—ï¼Œè€Œ39ï¼…æ¥å—äº†ä¾çˆ±æ›¿å°¼å¼•å¯¼çš„åºåˆ—ã€‚å°†è¿‘60ï¼…çš„æ€»äººå£åœ¨ä½¿ç”¨ç¬¬ä¸€ç§ALKæŠ‘åˆ¶å‰‚ä¹‹å‰æ¥å—äº†åŒ–ç–—ã€‚ç ”ç©¶äººç¾¤çš„OSä¸­ä½æ•°ä¸º28ä¸ªæœˆï¼Œæ¥å—1ç§ALKæŠ‘åˆ¶å‰‚çš„æ‚£è€…ä¸º15ä¸ªæœˆï¼Œæ¥å—2ç§ALKæŠ‘åˆ¶å‰‚çš„æ‚£è€…ä¸º42ä¸ªæœˆï¼Œæ¥å—3-4ç§ALKæŠ‘åˆ¶å‰‚çš„æ‚£è€…ä¸º56ä¸ªæœˆã€‚ç¬¬ä¸€ç§ALKæŠ‘åˆ¶å‰‚çš„è¾ƒé•¿DOTä¸ç¬¬äºŒç§ALKæŠ‘åˆ¶å‰‚çš„DOTå¢åŠ æœ‰å…³ï¼ˆp <0.0001ï¼‰ï¼Œç¬¬äºŒç§ALKæŠ‘åˆ¶å‰‚çš„è¾ƒé•¿DOTä¸ç¬¬ä¸‰ç§ALKæŠ‘åˆ¶å‰‚çš„DOTå¢åŠ æœ‰å…³ï¼ˆp <0.00010001ï¼‰ã€‚å¼•å…¥æ–°çš„ALKæŠ‘åˆ¶å‰‚åï¼Œè¿™é¡¹ç ”ç©¶æä¾›äº†æœ‰å…³ç°å®ä¸–ç•Œæ²»ç–—æ¨¡å¼çš„åˆæ­¥ä¿¡æ¯ï¼Œå¹¶æ”¯æŒé¡ºåºæ€§ALKç–—æ³•çš„ä½¿ç”¨ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32725451[0m

Title: Effects of high-intensity interval training on gut microbiota profiles in 12 months' old ICR mice.

Journal: Journal of physiology and biochemistry (J. Physiol. Biochem.)

Date: 2020-Jul

Abstrct_EN: High-intensity interval training (HIT) has been proposed to exert multiple beneficial effects and positively affect gut microbiota, while how HIT would affect gut microbiota profiles in middle-aged mice remain unreported. Male ICR mice (12Â months old) were divided into two groups, i.e., control group (CON) and HIT exercise group (HIT) given HIT running with a total of 7Â weeks. Fecal content from the gut was collected eventually and gut microbiota were determined via 16S rRNA gene sequencing. Compared with CON group, mice from HIT group exhibited improved gut microbial diversity including increased Shannon index. Compared with the CON group, at the phylum level, the relative abundance of Proteobacteria and TM7 was significantly decreased and increased, respectively, from HIT group. At the genera level, HIT group had significantly increased Dorea and Dehalobacterium, while decreased Candidatus Arthromitus. PICRUSt analysis at level 2 and level 3 of KEGG pathways demonstrated that the cecal microbiota of mice from HIT group had significantly enriched pathways involved in carbohydrate metabolism, signal transduction mechanisms, and transcription, while reduced pathways involved in renal cell carcinoma, Huntington's disease, pathways in cancer, various types of N-glycan biosynthesis, Alzheimer's disease, glycan biosynthesis and metabolism, lipopolysaccharide biosynthesis, cell motility and secretion, and lipopolysaccharide biosynthesis proteins. In conclusion, HIT could dynamically alter gut microbiota profiles in middle-aged mice. How altered gut microbiota profiles could affect the biological functions of HIT need to be further explored.

Abstrct_CN: å·²æå‡ºé«˜å¼ºåº¦é—´æ­‡è®­ç»ƒï¼ˆHITï¼‰å‘æŒ¥å¤šç§æœ‰ç›Šä½œç”¨å¹¶ç§¯æå½±å“è‚ é“èŒç¾¤ï¼Œè€ŒHITå°†å¦‚ä½•å½±å“ä¸­å¹´å°é¼ çš„è‚ é“èŒç¾¤ç‰¹å¾ä»æœªæŠ¥é“ã€‚å°†é›„æ€§ICRå°é¼ ï¼ˆ12ä¸ªæœˆå¤§ï¼‰åˆ†ä¸ºä¸¤ç»„ï¼Œå³å¯¹ç…§ç»„ï¼ˆCONï¼‰å’ŒHITè¿åŠ¨ç»„ï¼ˆHITï¼‰è¿›è¡ŒHITè·‘æ­¥ï¼Œæ€»å…±è¿›è¡Œ7å‘¨ã€‚æœ€ç»ˆä»è‚ é“æ”¶é›†ç²ªä¾¿å«é‡ï¼Œå¹¶é€šè¿‡16S rRNAåŸºå› æµ‹åºç¡®å®šè‚ é“èŒç¾¤ã€‚ä¸CONç»„ç›¸æ¯”ï¼ŒHITç»„å°é¼ è¡¨ç°å‡ºæ”¹å–„çš„è‚ é“å¾®ç”Ÿç‰©å¤šæ ·æ€§ï¼ŒåŒ…æ‹¬å¢åŠ çš„ShannonæŒ‡æ•°ã€‚ä¸CONç»„ç›¸æ¯”ï¼ŒHITç»„åœ¨é—¨æ°´å¹³ä¸Šï¼ŒProteobacteriaå’ŒTM7çš„ç›¸å¯¹ä¸°åº¦åˆ†åˆ«æ˜¾ç€é™ä½å’Œå‡é«˜ã€‚åœ¨å±æ°´å¹³ä¸Šï¼ŒHITç»„çš„Doreaå’ŒDehalobacteriumæ˜æ˜¾å¢åŠ ï¼Œè€ŒArtandomituså‡ä¸é…µæ¯åˆ™å‡å°‘ã€‚ KEGGé€”å¾„ç¬¬2çº§å’Œç¬¬3çº§çš„PICRUStåˆ†æè¡¨æ˜ï¼ŒHITç»„å°é¼ çš„ç›²è‚ èŒç¾¤å…·æœ‰ä¸°å¯Œçš„å‚ä¸ç¢³æ°´åŒ–åˆç‰©ä»£è°¢ï¼Œä¿¡å·è½¬å¯¼æœºåˆ¶å’Œè½¬å½•çš„é€”å¾„ï¼Œè€Œå‡å°‘äº†æ¶‰åŠè‚¾ç»†èƒç™Œï¼Œäº¨å»·é¡¿èˆè¹ˆç—…çš„é€”å¾„åœ¨ç™Œç—‡ä¸­ï¼Œå„ç§ç±»å‹çš„N-èšç³–ç”Ÿç‰©åˆæˆï¼Œé˜¿å°”èŒ¨æµ·é»˜æ°ç—…ï¼Œèšç³–ç”Ÿç‰©åˆæˆå’Œä»£è°¢ï¼Œè„‚å¤šç³–ç”Ÿç‰©åˆæˆï¼Œç»†èƒè¿åŠ¨å’Œåˆ†æ³Œä»¥åŠè„‚å¤šç³–ç”Ÿç‰©åˆæˆè›‹ç™½ã€‚æ€»ä¹‹ï¼ŒHITå¯ä»¥åŠ¨æ€æ”¹å˜ä¸­å¹´å°é¼ çš„è‚ é“èŒç¾¤ç‰¹å¾ã€‚è‚ é“å¾®ç”Ÿç‰©ç¾¤çš„å˜åŒ–å¦‚ä½•å½±å“HITçš„ç”Ÿç‰©å­¦åŠŸèƒ½æœ‰å¾…è¿›ä¸€æ­¥æ¢è®¨ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32725165[0m

Title: In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.

Journal: Bioscience reports (Biosci. Rep.)

Date: 2020-Jul

Abstrct_EN: Glioma is the common histological subtype of malignancy in central nervous system, with a high morbidity and mortality. Cancer stem cells (CSCs) play an important role in regulating the tumorigenesis and progression of glioma, however, the prognostic biomarkers and therapeutic targets associated with CSC characteristics have not been fully acknowledged in glioma. In order to identify the prognostic stemness-related genes (SRGs) of glioma in silico, the RNA sequencing data of patients with glioma were retrieved from The Cancer Genome Atlas (TCGA) databases. The mRNA expression-based stemness index (mRNAsi) was significantly associated with the glioma histologic grade, isocitrate dehydrogenase 1 (IDH1) mutation and overall survival of glioma patients by the nonparametric test and Kaplan-Meier survival analysis. A total of 340 SRGs were identified as the overlapped stemness-related differential expressed genes (DEGs) of different histologic grade screened by the univariate Cox analysis. Based on 11 prognostic SRGs, the predict nomogram was constructed with the AUC of 0.832. Moreover, the risk score of the nomogram was an independent prognostic factor, indicating its significant applicability. Besides other 8 reported biomarkers of glioma, we found that F2RL2, CLCNKA and LOXL4 were firstly identified as prognostic biomarkers for glioma. In conclusion, this bioinformatics study demonstrates the mRNAsi as a reliable index for the IDH1 mutation, histologic grade and OS of glioma patients andprovides a well-applied model for predicting the OS for patients with glioma based on prognostic SRGs. Additionally, this in silico study also identifies three novel prognostic biomarkers (F2RL2, CLCNKA and LOXL4) for glioma patients.

Abstrct_CN: èƒ¶è´¨ç˜¤æ˜¯ä¸­æ¢ç¥ç»ç³»ç»Ÿæ¶æ€§è‚¿ç˜¤çš„å¸¸è§ç»„ç»‡å­¦äºšå‹ï¼Œå‘ç—…ç‡å’Œæ­»äº¡ç‡é«˜ã€‚ç™Œç—‡å¹²ç»†èƒï¼ˆCSCï¼‰åœ¨è°ƒèŠ‚ç¥ç»èƒ¶è´¨ç˜¤çš„å‘ç”Ÿå’Œå‘å±•ä¸­èµ·ç€é‡è¦ä½œç”¨ï¼Œä½†æ˜¯ï¼Œä¸CSCç‰¹å¾ç›¸å…³çš„é¢„åç”Ÿç‰©æ ‡å¿—ç‰©å’Œæ²»ç–—é¶æ ‡åœ¨ç¥ç»èƒ¶è´¨ç˜¤ä¸­å°šæœªå¾—åˆ°å……åˆ†è®¤è¯†ã€‚ä¸ºäº†é‰´å®šç¥ç»èƒ¶è´¨ç˜¤çš„é¢„åå¹²æ€§ç›¸å…³åŸºå› ï¼ˆSRGï¼‰ï¼Œä»ç™Œç—‡åŸºå› ç»„å›¾è°±ï¼ˆTCGAï¼‰æ•°æ®åº“ä¸­æ£€ç´¢äº†ç¥ç»èƒ¶è´¨ç˜¤æ‚£è€…çš„RNAæµ‹åºæ•°æ®ã€‚é€šè¿‡éå‚æ•°æµ‹è¯•å’ŒKaplan-Meierç”Ÿå­˜åˆ†æï¼ŒåŸºäºmRNAè¡¨è¾¾çš„å¹²åº¦æŒ‡æ•°ï¼ˆmRNAsiï¼‰ä¸ç¥ç»èƒ¶è´¨ç˜¤çš„ç»„ç»‡å­¦ç­‰çº§ï¼Œå¼‚æŸ æª¬é…¸è„±æ°¢é…¶1ï¼ˆIDH1ï¼‰çªå˜å’Œç¥ç»èƒ¶è´¨ç˜¤æ‚£è€…çš„æ€»ä½“ç”Ÿå­˜ç‡æ˜¾ç€ç›¸å…³ã€‚é€šè¿‡å•å˜é‡Coxåˆ†æç­›é€‰å‡ºæ€»å…±340ä¸ªSRGï¼Œå®ƒä»¬æ˜¯ä¸åŒç»„ç»‡å­¦ç­‰çº§çš„é‡å å¹²æ€§ç›¸å…³å·®å¼‚è¡¨è¾¾åŸºå› ï¼ˆDEGï¼‰ã€‚åŸºäº11ä¸ªé¢„åçš„SRGï¼Œä»¥0.832çš„AUCæ„å»ºé¢„æµ‹åˆ—çº¿å›¾ã€‚æ­¤å¤–ï¼Œåˆ—çº¿å›¾çš„é£é™©è¯„åˆ†æ˜¯ç‹¬ç«‹çš„é¢„åå› ç´ ï¼Œè¡¨æ˜å…¶æ˜¾ç€çš„é€‚ç”¨æ€§ã€‚é™¤äº†æŠ¥å‘Šçš„å…¶ä»–8ç§ç¥ç»èƒ¶è´¨ç˜¤ç”Ÿç‰©æ ‡å¿—ç‰©å¤–ï¼Œæˆ‘ä»¬è¿˜å‘ç°F2RL2ï¼ŒCLCNKAå’ŒLOXL4é¦–å…ˆè¢«é‰´å®šä¸ºç¥ç»èƒ¶è´¨ç˜¤çš„é¢„åç”Ÿç‰©æ ‡å¿—ç‰©ã€‚æ€»ä¹‹ï¼Œè¿™é¡¹ç”Ÿç‰©ä¿¡æ¯å­¦ç ”ç©¶è¡¨æ˜ï¼ŒmRNAsiå¯ä½œä¸ºèƒ¶è´¨ç˜¤æ‚£è€…IDH1çªå˜ï¼Œç»„ç»‡å­¦ç­‰çº§å’ŒOSçš„å¯é æŒ‡æ ‡ï¼Œå¹¶æä¾›äº†ä¸€ç§åŸºäºé¢„åæ€§SRGsé¢„æµ‹èƒ¶è´¨ç˜¤æ‚£è€…OSçš„è‰¯å¥½æ¨¡å‹ã€‚æ­¤å¤–ï¼Œè¿™é¡¹è®¡ç®—æœºæ¨¡æ‹Ÿç ”ç©¶è¿˜ä¸ºç¥ç»èƒ¶è´¨ç˜¤æ‚£è€…ç¡®å®šäº†ä¸‰ç§æ–°çš„é¢„åç”Ÿç‰©æ ‡å¿—ç‰©ï¼ˆF2RL2ï¼ŒCLCNKAå’ŒLOXL4ï¼‰ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724874[0m

Title: Genetic analysis in the clinical management of biliary tract cancer.

Journal: Annals of gastroenterological surgery (Ann Gastroenterol Surg)

Date: 2020-Jul

Abstrct_EN: Biliary tract cancer (BTC) is clinically and pathologically heterogeneous and responds inadequately to treatment. A small section of patients develop resectable disease, although the relapse rates are high; the benefits of adjuvant capecitabine chemotherapy for BTC are now understood, and gemcitabine-based combination chemotherapy is the first line of therapeutic strategy for BTC; however, alternative therapy for BTC is not known. Genomic profiling can provide detailed information regarding the carcinogenesis, identification, and therapy for BTC. Currently, confirmed restorative targets for BTC are lacking. In this review, we aimed to analyzeÂ the preclinical and clinical implications of a spectrum of genomic alterations associated with new potentially remedial targets. We focused on eight draggable genes for BTC, which were described as having evidence of therapeutic impact (evidence level 2A-3B) based on the clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment; these include ERBB2, NTRK1, RNF43, CDK6, CDKN2B, FGFR2, IDH1, and IDH2. Moreover, some of the BTC present microsatellite instability, hypermutation, and germline variants, which we also reviewed. Finally, we discussed the therapeutic options based on the next-generation sequencing findings in BTC. Studies have demonstrated that BTC includes subgroups with individually distinct driver mutations, most of which will be targeted with new treatment plans.

Abstrct_CN: èƒ†é“ç™Œï¼ˆBTCï¼‰åœ¨ä¸´åºŠå’Œç—…ç†ä¸Šæ˜¯å¼‚è´¨æ€§çš„ï¼Œå¯¹æ²»ç–—çš„ååº”ä¸è¶³ã€‚å°½ç®¡å¤å‘ç‡å¾ˆé«˜ï¼Œä½†æ˜¯ä¸€å°éƒ¨åˆ†æ‚£è€…ä¼šå‘å±•ä¸ºå¯åˆ‡é™¤çš„ç–¾ç—…ã€‚ç°åœ¨å·²ç»äº†è§£äº†å¡åŸ¹ä»–æ»¨è¾…åŠ©åŒ–ç–—å¯¹BTCçš„ç›Šå¤„ï¼ŒåŸºäºå‰è¥¿ä»–æ»¨çš„è”åˆåŒ–ç–—æ˜¯BTCæ²»ç–—ç­–ç•¥çš„ç¬¬ä¸€çº¿ï¼›ä½†æ˜¯ï¼ŒBTCçš„æ›¿ä»£ç–—æ³•å°šä¸æ¸…æ¥šã€‚åŸºå› ç»„æ¦‚å†µåˆ†æå¯ä»¥æä¾›æœ‰å…³BTCçš„è‡´ç™Œæ€§ï¼Œé‰´å®šå’Œæ²»ç–—çš„è¯¦ç»†ä¿¡æ¯ã€‚ç›®å‰ï¼Œç¼ºä¹ç¡®å®šçš„BTCæ¢å¤ç›®æ ‡ã€‚åœ¨è¿™ç¯‡ç»¼è¿°ä¸­ï¼Œæˆ‘ä»¬æ—¨åœ¨åˆ†æä¸æ–°çš„æ½œåœ¨æ²»ç–—é¶æ ‡ç›¸å…³çš„ä¸€ç³»åˆ—åŸºå› ç»„æ”¹å˜çš„ä¸´åºŠå‰å’Œä¸´åºŠæ„ä¹‰ã€‚æˆ‘ä»¬é›†ä¸­ç ”ç©¶äº†BTCçš„å…«ä¸ªå¯æ‹–åŠ¨åŸºå› ï¼Œè¿™äº›åŸºå› è¢«æè¿°ä¸ºå…·æœ‰æ²»ç–—æ•ˆæœçš„è¯æ®ï¼ˆè¯æ®æ°´å¹³2A-3Bï¼‰ï¼ŒåŸºäºä¸‹ä¸€ä»£æµ‹åºåœ¨ç™Œç—‡è¯Šæ–­å’Œæ²»ç–—ä¸­çš„ä¸´åºŠå®è·µæŒ‡å—ã€‚è¿™äº›åŒ…æ‹¬ERBB2ï¼ŒNTRK1ï¼ŒRNF43ï¼ŒCDK6ï¼ŒCDKN2Bï¼ŒFGFR2ï¼ŒIDH1å’ŒIDH2ã€‚æ­¤å¤–ï¼Œä¸€äº›BTCå­˜åœ¨å¾®å«æ˜Ÿä¸ç¨³å®šæ€§ï¼Œè¶…çªå˜å’Œç§ç³»å˜å¼‚ï¼Œæˆ‘ä»¬ä¹Ÿå¯¹æ­¤è¿›è¡Œäº†å›é¡¾ã€‚æœ€åï¼Œæˆ‘ä»¬è®¨è®ºäº†åŸºäºBTCä¸­ä¸‹ä¸€ä»£æµ‹åºå‘ç°çš„æ²»ç–—é€‰æ‹©ã€‚ç ”ç©¶è¡¨æ˜ï¼ŒBTCåŒ…æ‹¬å…·æœ‰å„è‡ªä¸åŒçš„é©±åŠ¨ç¨‹åºçªå˜çš„äºšç»„ï¼Œå…¶ä¸­å¤§å¤šæ•°å°†é’ˆå¯¹æ–°çš„æ²»ç–—è®¡åˆ’ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724790[0m

Title: Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer.

Journal: International journal of genomics (Int J Genomics)

Date: No article date

Abstrct_EN: Breast cancer development and progression involve both germline and somatic mutations. High-throughput genotyping and next-generation sequencing technologies have enabled discovery of genetic risk variants and acquired somatic mutations driving the disease. However, the possible oncogenic interactions between germline genetic risk variants and somatic mutations in triple-negative breast cancer (TNBC) and non-triple-negative breast cancer (non-TNBC) have not been characterized. Here, we delineated the possible oncogenic interactions between genes containing germline and somatic mutations in TNBC and non-TNBC and investigated whether there are differences in gene expression and mutation burden between the two types of breast cancer. We addressed this problem by integrating germline mutation information from genome-wide association studies with somatic mutation information from next-generation sequencing using gene expression data as the intermediated phenotype. We performed network and pathway analyses to discover molecular networks and signalling pathways enriched for germline and somatic mutations. The investigation revealed signatures of differentially expressed and differentially somatic mutated genes between TNBC and non-TNBC. Network and pathway analyses revealed functionally related genes interacting in gene regulatory networks and multiple signalling pathways enriched for germline and somatic mutations for each type of breast cancer. Among the signalling pathways discovered included the DNA repair and Androgen and ATM signalling pathways for TNBC and the DNA damage response, molecular mechanisms of cancer, and ATM and GP6 signalling pathways for non-TNBC. The results show that integrative genomics is a powerful approach for delineating oncogenic interactions between genes containing germline and genes containing somatic mutations in TNBC and non-TNBC and establishes putative functional bridges between genetic and somatic alterations and the pathways they control in the two types of breast cancer.

Abstrct_CN: ä¹³è…ºç™Œçš„å‘ç”Ÿå’Œå‘å±•æ¶‰åŠç§ç³»å’Œä½“ç»†èƒçªå˜ã€‚é«˜é€šé‡åŸºå› åˆ†å‹å’Œä¸‹ä¸€ä»£æµ‹åºæŠ€æœ¯ä½¿äººä»¬èƒ½å¤Ÿå‘ç°é—ä¼ é£é™©å˜å¼‚å’Œé©±åŠ¨è¯¥ç–¾ç—…çš„è·å¾—æ€§ä½“ç»†èƒçªå˜ã€‚ç„¶è€Œï¼Œå°šæœªé‰´å®šå‡ºä¸‰é˜´æ€§ä¹³è…ºç™Œï¼ˆTNBCï¼‰å’Œéä¸‰é˜´æ€§ä¹³è…ºç™Œï¼ˆnon-TNBCï¼‰çš„ç§ç³»é—ä¼ é£é™©å˜å¼‚ä¸ä½“ç»†èƒçªå˜ä¹‹é—´å¯èƒ½çš„è‡´ç™Œç›¸äº’ä½œç”¨ã€‚åœ¨è¿™é‡Œï¼Œæˆ‘ä»¬æè¿°äº†TNBCå’ŒéTNBCä¸­åŒ…å«ç§ç³»å’Œä½“ç»†èƒçªå˜çš„åŸºå› ä¹‹é—´å¯èƒ½çš„è‡´ç™Œç›¸äº’ä½œç”¨ï¼Œå¹¶ç ”ç©¶äº†ä¸¤ç§ä¹³è…ºç™Œä¹‹é—´åœ¨åŸºå› è¡¨è¾¾å’Œçªå˜è´Ÿæ‹…æ–¹é¢æ˜¯å¦å­˜åœ¨å·®å¼‚ã€‚æˆ‘ä»¬é€šè¿‡ä½¿ç”¨åŸºå› è¡¨è¾¾æ•°æ®ä½œä¸ºä¸­é—´è¡¨å‹ï¼Œæ•´åˆäº†æ¥è‡ªå…¨åŸºå› ç»„å…³è”ç ”ç©¶çš„ç§ç³»çªå˜ä¿¡æ¯ä¸æ¥è‡ªä¸‹ä¸€ä»£æµ‹åºçš„ä½“ç»†èƒçªå˜ä¿¡æ¯ï¼Œä»è€Œè§£å†³äº†è¿™ä¸ªé—®é¢˜ã€‚æˆ‘ä»¬è¿›è¡Œäº†ç½‘ç»œå’Œé€”å¾„åˆ†æï¼Œä»¥å‘ç°ä¸°å¯Œäº†ç§ç³»å’Œä½“ç»†èƒçªå˜çš„åˆ†å­ç½‘ç»œå’Œä¿¡å·ä¼ å¯¼é€”å¾„ã€‚è°ƒæŸ¥æ˜¾ç¤ºäº†TNBCå’ŒéTNBCä¹‹é—´å·®å¼‚è¡¨è¾¾å’Œå·®å¼‚ä½“ç»†èƒçªå˜åŸºå› çš„ç‰¹å¾ã€‚ç½‘ç»œå’Œé€”å¾„åˆ†ææ­ç¤ºäº†ä¸åŠŸèƒ½ç›¸å…³çš„åŸºå› åœ¨åŸºå› è°ƒæ§ç½‘ç»œä¸­ç›¸äº’ä½œç”¨ï¼Œå¹¶ä¸”ä¸ºå¤šç§ç±»å‹çš„ä¹³è…ºç™Œçš„ç§ç³»å’Œä½“ç»†èƒçªå˜ä¸°å¯Œäº†å¤šç§ä¿¡å·ä¼ å¯¼é€”å¾„ã€‚å‘ç°çš„ä¿¡å·ä¼ å¯¼é€”å¾„åŒ…æ‹¬TNBCçš„DNAä¿®å¤ï¼Œé›„æ¿€ç´ å’ŒATMä¿¡å·ä¼ å¯¼é€”å¾„ä»¥åŠDNAæŸä¼¤ååº”ï¼Œç™Œç—‡çš„åˆ†å­æœºåˆ¶ä»¥åŠéTNBCçš„ATMå’ŒGP6ä¿¡å·ä¼ å¯¼é€”å¾„ã€‚ç»“æœè¡¨æ˜ï¼Œæ•´åˆåŸºå› ç»„å­¦æ˜¯æè¿°TNBCå’ŒéTNBCä¸­åŒ…å«ç§ç³»çš„åŸºå› ä¸åŒ…å«ä½“ç»†èƒçªå˜çš„åŸºå› ä¹‹é—´çš„è‡´ç™Œç›¸äº’ä½œç”¨çš„æœ‰æ•ˆæ–¹æ³•ï¼Œå¹¶å»ºç«‹äº†é—ä¼ å’Œä½“ç»†èƒå˜åŒ–ä¹‹é—´çš„æ¨å®šåŠŸèƒ½æ¡¥æ¢ï¼Œä»¥åŠå®ƒä»¬åœ¨ä¸¤ç§ç±»å‹çš„ä¹³è…ºä¸­æ§åˆ¶çš„é€”å¾„ç™Œç—‡ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724459[0m

Title: Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.

Journal: Theranostics (Theranostics)

Date: No article date

Abstrct_EN: <b>Background:</b> Triple-negative breast cancer (TNBC) is one of the most prevalent neoplastic diseases worldwide, but efficacious treatments for this pathological condition are still challenging. The lack of an effective targeted therapy also leads to a poor prognosis for patients affected by TNBC. In the present study, we repurposed the distinctive inhibitory effects of flubendazole, a traditional anthelmintic drug, towards the putative modulation of proliferation and migration of TNBC <i>in vitro and in vivo</i>. <b>Methods:</b> According to a series of experimental approaches, including immunofluorescence (IF), immunoblotting (IB), siRNA and GFP-mRFP-LC3 plasmid transfection, respectively, we have found that flubendazole is capable of inducing autophagic cell death and apoptosis, thus exerting some anti-proliferative and anti-migration activity in TNBC cells. The therapeutic effects of flubendazole were evaluated by xenograft mouse models, followed by immunohistochemistry (IHC), IF and IB. Changes in the gene expression profiles of flubendazole-treated TNBC cells were analyzed by RNA sequencing (RNA-seq) and validated by IB. The potential binding mode of flubendazole and EVA1A was predicted by molecular docking and demonstrated by site-directed mutagenesis. <b>Results:</b> We have presently found that flubendazole exhibits a considerable anti-proliferative activity <i>in vitro</i> and <i>in vivo</i>. Mechanistically, the induction of autophagic cell death appears to be pivotal for flubendazole-mediated growth inhibition of TNBC cells, whereas blocking autophagy was able to improve the survival rate and migration ability of flubendazole-treated TNBC cells. Specifically, RNA-seq analysis showed that flubendazole treatment could promote the up-regulation of EVA1A. Flubendazole may regulate autophagy and apoptosis by targeting EVA1A, thus affecting the mechanisms of TNBC proliferation and migration. Furthermore, Thr113 may be the key amino acid residues for the binding of flubendazole to EVA1A. <b>Conclusion:</b> Our results provide novel insights towards the putative anti-cancer efficacy of flubendazole. Furthermore, here we show that flubendazole could serve as a potential therapeutic drug in TNBC. Altogether, this study highlights the possibility of this repurposed autophagic inducer for future cancer treatments.

Abstrct_CN: <b>èƒŒæ™¯ï¼š</ b>ä¸‰é˜´æ€§ä¹³è…ºç™Œï¼ˆTNBCï¼‰æ˜¯ä¸–ç•Œä¸Šæœ€æ™®éçš„èµ˜ç”Ÿæ€§ç–¾ç—…ä¹‹ä¸€ï¼Œä½†æ˜¯å¯¹äºè¿™ç§ç—…ç†çŠ¶å†µçš„æœ‰æ•ˆæ²»ç–—ä»ç„¶å…·æœ‰æŒ‘æˆ˜æ€§ã€‚ç¼ºä¹æœ‰æ•ˆçš„é¶å‘æ²»ç–—è¿˜å¯¼è‡´å—TNBCå½±å“çš„æ‚£è€…é¢„åè¾ƒå·®ã€‚åœ¨æœ¬ç ”ç©¶ä¸­ï¼Œæˆ‘ä»¬å°†æ°Ÿè‹¯è¾¾å”‘ï¼ˆä¸€ç§ä¼ ç»Ÿçš„é©±è™«è¯ï¼‰çš„ç‹¬ç‰¹æŠ‘åˆ¶ä½œç”¨é‡æ–°å®šä½äºæ¨æµ‹çš„TNBCåœ¨ä½“å¤–å’Œä½“å†…çš„å¢æ®–å’Œè¿ç§»è°ƒèŠ‚ã€‚ <b>æ–¹æ³•ï¼š</ b>æ ¹æ®ä¸€ç³»åˆ—å®éªŒæ–¹æ³•ï¼ŒåŒ…æ‹¬å…ç–«è§å…‰ï¼ˆIFï¼‰ï¼Œå…ç–«å°è¿¹ï¼ˆIBï¼‰ï¼ŒsiRNAå’ŒGFP-mRFP-LC3è´¨ç²’è½¬æŸ“ï¼Œæˆ‘ä»¬å‘ç°flubendazoleèƒ½å¤Ÿè¯±å¯¼è‡ªå™¬ã€‚ç»†èƒæ­»äº¡å’Œå‡‹äº¡ï¼Œä»è€Œåœ¨TNBCç»†èƒä¸­å‘æŒ¥ä¸€äº›æŠ—å¢æ®–å’ŒæŠ—è¿ç§»æ´»æ€§ã€‚é€šè¿‡å¼‚ç§ç§»æ¤å°é¼ æ¨¡å‹ï¼Œéšåå…ç–«ç»„ç»‡åŒ–å­¦ï¼ˆIHCï¼‰ï¼ŒIFå’ŒIBè¯„ä¼°äº†æ°Ÿè‹¯è¾¾å”‘çš„æ²»ç–—æ•ˆæœã€‚æ°Ÿè‹¯è¾¾å”‘å¤„ç†çš„TNBCç»†èƒåŸºå› è¡¨è¾¾è°±çš„å˜åŒ–é€šè¿‡RNAæµ‹åºï¼ˆRNA-seqï¼‰åˆ†æå¹¶é€šè¿‡IBéªŒè¯ã€‚æ°Ÿè‹¯è¾¾å”‘å’ŒEVA1Açš„æ½œåœ¨ç»“åˆæ¨¡å¼é€šè¿‡åˆ†å­å¯¹æ¥é¢„æµ‹ï¼Œå¹¶é€šè¿‡å®šç‚¹è¯±å˜è¯æ˜ã€‚ <b>ç»“æœï¼š</ b>æˆ‘ä»¬ç›®å‰å‘ç°ï¼Œæ°Ÿè‹¯è¾¾å”‘<i>åœ¨ä½“å¤–</ i>å’Œåœ¨ä½“å†…<i>å…·æœ‰ç›¸å½“å¤§çš„æŠ—å¢æ®–æ´»æ€§ã€‚ä»æœºåˆ¶ä¸Šè®²ï¼Œè‡ªå™¬ç»†èƒæ­»äº¡çš„è¯±å¯¼ä¼¼ä¹æ˜¯ç”±flubendazoleä»‹å¯¼çš„TNBCç»†èƒç”Ÿé•¿æŠ‘åˆ¶çš„å…³é”®ï¼Œè€Œé˜»æ–­è‡ªå™¬åˆ™èƒ½å¤Ÿæé«˜flubendazoleå¤„ç†çš„TNBCç»†èƒçš„å­˜æ´»ç‡å’Œè¿ç§»èƒ½åŠ›ã€‚å…·ä½“æ¥è¯´ï¼ŒRNA-seqåˆ†æè¡¨æ˜ï¼Œæ°Ÿè‹¯è¾¾å”‘å¤„ç†å¯ä»¥ä¿ƒè¿›EVA1Açš„ä¸Šè°ƒã€‚æ°Ÿè‹¯è¾¾å”‘å¯é€šè¿‡é¶å‘EVA1Aè°ƒèŠ‚è‡ªå™¬å’Œå‡‹äº¡ï¼Œä»è€Œå½±å“TNBCå¢æ®–å’Œè¿ç§»çš„æœºåˆ¶ã€‚æ­¤å¤–ï¼ŒThr113å¯èƒ½æ˜¯æ°Ÿè‹¯è¾¾å”‘ä¸EVA1Aç»“åˆçš„å…³é”®æ°¨åŸºé…¸æ®‹åŸºã€‚ <b>ç»“è®ºï¼š</ b>æˆ‘ä»¬çš„ç»“æœä¸ºæ°Ÿè‹¯è¾¾å”‘çš„å‡å®šæŠ—ç™ŒåŠŸæ•ˆæä¾›äº†æ–°é¢–çš„è§è§£ã€‚æ­¤å¤–ï¼Œåœ¨è¿™é‡Œæˆ‘ä»¬æ˜¾ç¤ºäº†æ°Ÿè‹¯è¾¾å”‘å¯ä»¥ä½œä¸ºTNBCä¸­æ½œåœ¨çš„æ²»ç–—è¯ç‰©ã€‚æ€»è€Œè¨€ä¹‹ï¼Œè¿™é¡¹ç ”ç©¶çªå‡ºäº†è¿™ç§é‡æ–°å®šä½çš„è‡ªå™¬è¯±å¯¼å‰‚ç”¨äºæœªæ¥ç™Œç—‡æ²»ç–—çš„å¯èƒ½æ€§ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724444[0m

Title: A robust method for the rapid detection of microsatellite instability in colorectal cancer.

Journal: Oncology letters (Oncol Lett)

Date: 2020-Aug

Abstrct_EN: Although several computational tools using next-generation sequencing (NGS) data have been proposed to detect microsatellite instability (MSI) status, they still have limitations and need improvement. We developed a NovoPM-MSI method to detect MSI status based on NGS data. This method evaluated target mononucleotide microsatellite loci that were sequenced during targeted gene enrichment analysis and reported sample instability score as the fraction of unstable loci within the target set after assessing locus instability by comparing length distribution in paired tumor-normal samples. We validated this method against the conventional MSI-PCR method in 113 paired colorectal cancer (CRC) specimens and compared the performance of NovoPM-MSI to that of mSINGS and MANTIS in accuracy and runtime efficiency. By using the MSI status from MSI-PCR as the gold standard, the three computational methods showed the same sensitivity of 88.9% but different specificities (NovoPM-MSI 97.1%, MANTIS 86.5% and mSINGS 99.0%). Only NovoPM-MSI could greatly improve both the sensitivity and specificity by setting an ambiguous interval. MANTIS had the shortest average runtime (16.3 sec), followed by NovoPM-MSI (18.3 sec) and mSINGS (109.0 sec). In short, the NovoPM-MSI method provides a fast and reliable MSI detection method with accuracy comparable to MSI-PCR in paired CRC samples.

Abstrct_CN: å°½ç®¡å·²ç»æå‡ºäº†å‡ ç§ä½¿ç”¨ä¸‹ä¸€ä»£æµ‹åºï¼ˆNGSï¼‰æ•°æ®çš„è®¡ç®—å·¥å…·æ¥æ£€æµ‹å¾®å«æ˜Ÿä¸ç¨³å®šæ€§ï¼ˆMSIï¼‰çŠ¶æ€ï¼Œä½†å®ƒä»¬ä»ç„¶æœ‰å±€é™æ€§ï¼Œéœ€è¦æ”¹è¿›ã€‚æˆ‘ä»¬å¼€å‘äº†ä¸€ç§NovoPM-MSIæ–¹æ³•ï¼Œç”¨äºæ ¹æ®NGSæ•°æ®æ£€æµ‹MSIçŠ¶æ€ã€‚è¯¥æ–¹æ³•è¯„ä¼°äº†åœ¨é¶åŸºå› å¯Œé›†åˆ†æè¿‡ç¨‹ä¸­æµ‹åºçš„é¶å•æ ¸è‹·é…¸å¾®å«æ˜ŸåŸºå› åº§ï¼Œå¹¶é€šè¿‡æ¯”è¾ƒé…å¯¹çš„æ­£å¸¸è‚¿ç˜¤æ ·æœ¬ä¸­çš„é•¿åº¦åˆ†å¸ƒæ¥è¯„ä¼°åŸºå› åº§ä¸ç¨³å®šæ€§åï¼Œå°†æ ·æœ¬ä¸ç¨³å®šæ€§åˆ†æ•°æŠ¥å‘Šä¸ºç›®æ ‡é›†ä¸­ä¸ç¨³å®šåŸºå› åº§çš„åˆ†æ•°ã€‚æˆ‘ä»¬åœ¨113ä¸ªé…å¯¹çš„ç»“ç›´è‚ ç™Œï¼ˆCRCï¼‰æ ‡æœ¬ä¸­é’ˆå¯¹ä¼ ç»ŸMSI-PCRæ–¹æ³•éªŒè¯äº†è¯¥æ–¹æ³•ï¼Œå¹¶æ¯”è¾ƒäº†NovoPM-MSIä¸mSINGSå’ŒMANTISåœ¨å‡†ç¡®æ€§å’Œè¿è¡Œæ•ˆç‡æ–¹é¢çš„æ€§èƒ½ã€‚é€šè¿‡ä½¿ç”¨MSI-PCRçš„MSIçŠ¶æ€ä½œä¸ºé‡‘æ ‡å‡†ï¼Œè¿™ä¸‰ç§è®¡ç®—æ–¹æ³•æ˜¾ç¤ºå‡ºç›¸åŒçš„çµæ•åº¦88.9ï¼…ï¼Œä½†ç‰¹å¼‚æ€§ä¸åŒï¼ˆNovoPM-MSI 97.1ï¼…ï¼ŒMANTIS 86.5ï¼…å’ŒmSINGS 99.0ï¼…ï¼‰ã€‚é€šè¿‡è®¾ç½®ä¸æ˜ç¡®çš„é—´éš”ï¼Œåªæœ‰NovoPM-MSIæ‰èƒ½å¤§å¤§æé«˜æ•æ„Ÿæ€§å’Œç‰¹å¼‚æ€§ã€‚ MANTISçš„å¹³å‡è¿è¡Œæ—¶é—´æœ€çŸ­ï¼ˆ16.3ç§’ï¼‰ï¼Œå…¶æ¬¡æ˜¯NovoPM-MSIï¼ˆ18.3ç§’ï¼‰å’ŒmSINGSï¼ˆ109.0ç§’ï¼‰ã€‚ç®€è€Œè¨€ä¹‹ï¼ŒNovoPM-MSIæ–¹æ³•æä¾›äº†ä¸€ç§å¿«é€Ÿå¯é çš„MSIæ£€æµ‹æ–¹æ³•ï¼Œå…¶å‡†ç¡®æ€§å¯ä¸é…å¯¹CRCæ ·æœ¬ä¸­çš„MSI-PCRåª²ç¾ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724428[0m

Title: Long non-coding RNA EWSAT1 contributes to the proliferation and invasion of glioma by sponging miR-152-3p.

Journal: Oncology letters (Oncol Lett)

Date: 2020-Aug

Abstrct_EN: Long non-coding RNAs (lncRNA) are a type of ncRNA with a length ranging from 200-1,000 nucleotides. Previous studies have confirmed that the lncRNA Ewing sarcoma associated transcript 1 (EWSAT1) exerts regulatory roles in cancer development and progression. However, its clinical significance in glioma remains unknown. In the present study, RNA-sequencing data from the Gene Expression Omnibus database and The Cancer Genome Atlas was explored to investigate the association between EWSAT1 expression and prognosis in patients with glioma. Increased EWSAT1 was associated with the presence of necrosis on magnetic resonance imaging scans in patients with glioma. Furthermore, knockdown of EWSAT1 was indicated to suppress the proliferative and invasive abilities of glioblastoma cell lines using Cell Counting Kit-8 and Transwell assays. Additionally, microRNA (miR)-152-3p was identified as a potential target of EWSAT1. The present study demonstrated that EWSAT1 interacted directly with miR-152-3p, and rescue experiments confirmed that EWSAT1 participated in glioma development by suppressing miR-152-3p. These results indicated that EWSAT1 is involved in the occurrence and progression of glioma, and may serve as a novel target and potential prognostic biomarker of glioma treatment.

Abstrct_CN: é•¿éç¼–ç RNAï¼ˆlncRNAï¼‰æ˜¯ä¸€ç§ncRNAï¼Œé•¿åº¦èŒƒå›´ä¸º200-1,000ä¸ªæ ¸è‹·é…¸ã€‚å…ˆå‰çš„ç ”ç©¶å·²ç»è¯å®ï¼ŒlncRNAå°¤å› è‚‰ç˜¤ç›¸å…³è½¬å½•æœ¬1ï¼ˆEWSAT1ï¼‰åœ¨ç™Œç—‡çš„å‘å±•å’Œè¿›ç¨‹ä¸­å‘æŒ¥è°ƒèŠ‚ä½œç”¨ã€‚ç„¶è€Œï¼Œå…¶åœ¨ç¥ç»èƒ¶è´¨ç˜¤ä¸­çš„ä¸´åºŠæ„ä¹‰ä»ç„¶æœªçŸ¥ã€‚åœ¨æœ¬ç ”ç©¶ä¸­ï¼Œæ¢ç´¢äº†æ¥è‡ªGene Expression Omnibusæ•°æ®åº“å’ŒThe Cancer Genome Atlasçš„RNAæµ‹åºæ•°æ®ï¼Œä»¥ç ”ç©¶EWSAT1è¡¨è¾¾ä¸ç¥ç»èƒ¶è´¨ç˜¤æ‚£è€…é¢„åä¹‹é—´çš„å…³ç³»ã€‚èƒ¶è´¨ç˜¤æ‚£è€…çš„ç£å…±æŒ¯æˆåƒæ‰«ææ˜¾ç¤ºï¼ŒEWSAT1å‡é«˜ä¸åæ­»æœ‰å…³ã€‚æ­¤å¤–ï¼Œä½¿ç”¨ç»†èƒè®¡æ•°è¯•å‰‚ç›’8ï¼ˆCell Counting Kit-8ï¼‰å’ŒTranswellåˆ†æè¡¨æ˜ï¼Œæ•²ä½EWSAT1å¯ä»¥æŠ‘åˆ¶èƒ¶è´¨æ¯ç»†èƒç˜¤ç»†èƒç³»çš„å¢æ®–å’Œä¾µè¢­èƒ½åŠ›ã€‚æ­¤å¤–ï¼ŒmicroRNAï¼ˆmiRï¼‰-152-3pè¢«ç¡®å®šä¸ºEWSAT1çš„æ½œåœ¨ç›®æ ‡ã€‚æœ¬ç ”ç©¶è¡¨æ˜EWSAT1ä¸miR-152-3pç›´æ¥ç›¸äº’ä½œç”¨ï¼Œæ•‘æ´å®éªŒè¯å®EWSAT1é€šè¿‡æŠ‘åˆ¶miR-152-3på‚ä¸äº†ç¥ç»èƒ¶è´¨ç˜¤çš„å‘å±•ã€‚è¿™äº›ç»“æœè¡¨æ˜EWSAT1å‚ä¸èƒ¶è´¨ç˜¤çš„å‘ç”Ÿå’Œå‘å±•ï¼Œå¹¶å¯èƒ½ä½œä¸ºèƒ¶è´¨ç˜¤æ²»ç–—çš„æ–°ç›®æ ‡å’Œæ½œåœ¨çš„ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724412[0m

Title: Identification of hub genes involved in the occurrence and development of hepatocellular carcinoma via bioinformatics analysis.

Journal: Oncology letters (Oncol Lett)

Date: 2020-Aug

Abstrct_EN: Hepatocellular carcinoma (HCC) is a heterogeneous malignancy, which is a major cause of cancer morbidity and mortality worldwide. Thus, the aim of the present study was to identify the hub genes and underlying pathways of HCC via bioinformatics analyses. The present study screened three datasets, including GSE112790, GSE84402 and GSE74656 from the Gene Expression Omnibus (GEO) database, and downloaded the RNA-sequencing of HCC from The Cancer Genome Atlas (TCGA) database. The differentially expressed genes (DEGs) in both the GEO and TCGA datasets were filtered, and the screened DEGs were subsequently analyzed for functional enrichment pathways. A protein-protein interaction (PPI) network was constructed, and hub genes were further screened to create the Kaplan-Meier curve using cBioPortal. The expression levels of hub genes were then validated in different datasets using the Oncomine database. In addition, associations between expression and tumor grade, hepatitis virus infection status, satellites and vascular invasion were assessed. A total of 126 DEGs were identified, containing 70 upregulated genes and 56 downregulated genes from the GEO and TCGA databases. By constructing the PPI network, the present study identified hub genes, including cyclin B1 (CCNB1), cell-division cycle protein 20 (CDC20), cyclin-dependent kinase 1, BUB1 mitotic checkpoint serine/threonine kinase Î² (BUB1B), cyclin A2, nucleolar and spindle associated protein 1, ubiquitin-conjugating enzyme E2 C (UBE2C) and ZW10 interactor. Furthermore, upregulated CCNB1, CDC20, BUB1B and UBE2C expression levels indicated worse disease-free and overall survival. Moreover, a meta-analysis of tumor and healthy tissues in the Oncomine database demonstrated that BUB1B and UBE2C were highly expressed in HCC. The present study also analyzed the data of HCC in TCGA database using univariate and multivariate Cox analyses, and demonstrated that BUB1B and UBE2C may be used as independent prognostic factors. In conclusion, the present study identified several genes and the signaling pathways that were associated with tumorigenesis using bioinformatics analyses, which could be potential targets for the diagnosis and treatment of HCC.

Abstrct_CN: è‚ç»†èƒç™Œï¼ˆHCCï¼‰æ˜¯ä¸€ç§å¼‚è´¨æ€§æ¶æ€§è‚¿ç˜¤ï¼Œæ˜¯å…¨ä¸–ç•Œç™Œç—‡å‘ç—…ç‡å’Œæ­»äº¡ç‡çš„ä¸»è¦åŸå› ã€‚å› æ­¤ï¼Œæœ¬ç ”ç©¶çš„ç›®çš„æ˜¯é€šè¿‡ç”Ÿç‰©ä¿¡æ¯å­¦åˆ†æé‰´å®šHCCçš„ä¸­å¿ƒåŸºå› å’Œæ½œåœ¨é€”å¾„ã€‚æœ¬ç ”ç©¶ä»Gene Expression Omnibusï¼ˆGEOï¼‰æ•°æ®åº“ä¸­ç­›é€‰äº†ä¸‰ä¸ªæ•°æ®é›†ï¼ŒåŒ…æ‹¬GSE112790ï¼ŒGSE84402å’ŒGSE74656ï¼Œå¹¶ä»The Cancer Genome Atlasï¼ˆTCGAï¼‰æ•°æ®åº“ä¸‹è½½äº†HCCçš„RNAåºåˆ—ã€‚è¿‡æ»¤äº†GEOå’ŒTCGAæ•°æ®é›†ä¸­çš„å·®å¼‚è¡¨è¾¾åŸºå› ï¼ˆDEGï¼‰ï¼Œéšååˆ†æäº†ç­›é€‰çš„DEGçš„åŠŸèƒ½å¯Œé›†é€”å¾„ã€‚æ„å»ºäº†è›‹ç™½è´¨-è›‹ç™½è´¨ç›¸äº’ä½œç”¨ï¼ˆPPIï¼‰ç½‘ç»œï¼Œå¹¶ä½¿ç”¨cBioPortalè¿›ä¸€æ­¥ç­›é€‰äº†æ¢çº½åŸºå› ä»¥åˆ›å»ºKaplan-Meieræ›²çº¿ã€‚ç„¶åä½¿ç”¨Oncomineæ•°æ®åº“åœ¨ä¸åŒçš„æ•°æ®é›†ä¸­éªŒè¯è½®æ¯‚åŸºå› çš„è¡¨è¾¾æ°´å¹³ã€‚æ­¤å¤–ï¼Œè¯„ä¼°äº†è¡¨è¾¾ä¸è‚¿ç˜¤ç­‰çº§ï¼Œè‚ç‚ç—…æ¯’æ„ŸæŸ“çŠ¶å†µï¼Œå«æ˜Ÿå’Œè¡€ç®¡æµ¸æ¶¦ä¹‹é—´çš„å…³è”ã€‚æ€»å…±é‰´å®šå‡º126ä¸ªDEGï¼Œå…¶ä¸­åŒ…å«æ¥è‡ªGEOå’ŒTCGAæ•°æ®åº“çš„70ä¸ªä¸Šè°ƒåŸºå› å’Œ56ä¸ªä¸‹è°ƒåŸºå› ã€‚é€šè¿‡æ„å»ºPPIç½‘ç»œï¼Œæœ¬ç ”ç©¶ç¡®å®šäº†é›†çº¿å™¨åŸºå› ï¼ŒåŒ…æ‹¬ç»†èƒå‘¨æœŸè›‹ç™½B1ï¼ˆCCNB1ï¼‰ï¼Œç»†èƒåˆ†è£‚å‘¨æœŸè›‹ç™½20ï¼ˆCDC20ï¼‰ï¼Œç»†èƒå‘¨æœŸè›‹ç™½ä¾èµ–æ€§æ¿€é…¶1ï¼ŒBUB1æœ‰ä¸åˆ†è£‚æ£€æŸ¥ç‚¹ä¸æ°¨é…¸/è‹æ°¨é…¸æ¿€é…¶Î²ï¼ˆBUB1Bï¼‰ï¼Œç»†èƒå‘¨æœŸè›‹ç™½A2 ï¼Œæ ¸ä»å’Œçººé”¤ä½“ç›¸å…³è›‹ç™½1ï¼Œæ³›ç´ ç»“åˆé…¶E2 Cï¼ˆUBE2Cï¼‰å’ŒZW10ç›¸äº’ä½œç”¨å­ã€‚æ­¤å¤–ï¼ŒCCNB1ï¼ŒCDC20ï¼ŒBUB1Bå’ŒUBE2Cè¡¨è¾¾æ°´å¹³ä¸Šè°ƒè¡¨æ˜æ— ç—…å’Œæ€»ä½“ç”Ÿå­˜çŠ¶å†µè¾ƒå·®ã€‚æ­¤å¤–ï¼Œåœ¨Oncomineæ•°æ®åº“ä¸­å¯¹è‚¿ç˜¤å’Œå¥åº·ç»„ç»‡çš„èŸèƒåˆ†æè¡¨æ˜ï¼ŒBUB1Bå’ŒUBE2Cåœ¨HCCä¸­é«˜åº¦è¡¨è¾¾ã€‚æœ¬ç ”ç©¶è¿˜ä½¿ç”¨å•å˜é‡å’Œå¤šå˜é‡Coxåˆ†æå¯¹TCGAæ•°æ®åº“ä¸­çš„HCCæ•°æ®è¿›è¡Œäº†åˆ†æï¼Œå¹¶è¯æ˜BUB1Bå’ŒUBE2Cå¯ä»¥ç”¨ä½œç‹¬ç«‹çš„é¢„åå› ç´ ã€‚æ€»ä¹‹ï¼Œæœ¬ç ”ç©¶ä½¿ç”¨ç”Ÿç‰©ä¿¡æ¯å­¦åˆ†æé‰´å®šäº†å‡ ç§ä¸è‚¿ç˜¤å‘ç”Ÿæœ‰å…³çš„åŸºå› å’Œä¿¡å·é€šè·¯ï¼Œè¿™å¯èƒ½æ˜¯è¯Šæ–­å’Œæ²»ç–—HCCçš„æ½œåœ¨ç›®æ ‡ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724403[0m

Title: Identification of glioblastoma-specific prognostic biomarkers via an integrative analysis of DNA methylation and gene expression.

Journal: Oncology letters (Oncol Lett)

Date: 2020-Aug

Abstrct_EN: Glioblastoma (GBM) is the most aggressive and lethal tumor of the central nervous system. The present study set out to identify reliable prognostic and predictive biomarkers for patients with GBM. RNA-sequencing data were obtained from The Cancer Genome Atlas database and DNA methylation data were downloaded using the University of California Santa Cruz-Xena database. The expression and methylation differences between patients with GBM, and survival times <1 and â‰¥1 year were investigated. A protein-protein interaction network was constructed and functional enrichment analyses of differentially expressed and methylated genes were performed. Hub genes were identified using the Cytoscape plug-in cytoHubba software. Survival analysis was performed using the survminer package, in order to determine the prognostic values of the hub genes. The present study identified 71 genes that were hypomethylated and expressed at high levels, and four genes that were hypermethylated and expressed at low levels in GBM. These genes were predominantly enriched in the 'JAK-STAT signaling pathway', 'transcriptional misregulation in cancer' and the 'ECM-receptor interaction', which are associated with GBM development. Among the 24 hub genes identified, 15 possessed potential prognostic value. An integrative analysis approach was implemented in order to analyze the association of DNA methylation with changes in gene expression and to assess the association of gene expression changes with GBM survival time. The results of the present study suggest that these 15 CpG-based genes may be useful and practical tools in predicting the prognosis of patients with GBM. However, future research on gene methylation and/or expression is required in order to develop personalized treatments for patients with GBM.

Abstrct_CN: èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ˆGBMï¼‰æ˜¯ä¸­æ¢ç¥ç»ç³»ç»Ÿä¸­æœ€å…·æ”»å‡»æ€§å’Œè‡´æ­»æ€§çš„è‚¿ç˜¤ã€‚æœ¬ç ”ç©¶ç€æ‰‹ç¡®å®šGBMæ‚£è€…å¯é çš„é¢„åå’Œé¢„æµ‹æ€§ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚ RNAæµ‹åºæ•°æ®ä»The Cancer Genome Atlasæ•°æ®åº“è·å¾—ï¼ŒDNAç”²åŸºåŒ–æ•°æ®ä½¿ç”¨åŠ åˆ©ç¦å°¼äºšå¤§å­¦åœ£å…‹é²æ–¯åˆ†æ ¡æ•°æ®åº“ä¸‹è½½ã€‚ç ”ç©¶GBMæ‚£è€…ä¹‹é—´çš„è¡¨è¾¾å’Œç”²åŸºåŒ–å·®å¼‚ï¼Œä»¥åŠç”Ÿå­˜æ—¶é—´<1å¹´å’Œâ‰¥1å¹´ã€‚æ„å»ºäº†è›‹ç™½è´¨-è›‹ç™½è´¨ç›¸äº’ä½œç”¨ç½‘ç»œï¼Œå¹¶è¿›è¡Œäº†å·®å¼‚è¡¨è¾¾å’Œç”²åŸºåŒ–åŸºå› çš„åŠŸèƒ½å¯Œé›†åˆ†æã€‚ä½¿ç”¨Cytoscapeæ’ä»¶cytoHubbaè½¯ä»¶è¯†åˆ«é›†çº¿å™¨åŸºå› ã€‚ä½¿ç”¨survminerè½¯ä»¶åŒ…è¿›è¡Œç”Ÿå­˜åˆ†æï¼Œä»¥ç¡®å®šè½®æ¯‚åŸºå› çš„é¢„åä»·å€¼ã€‚æœ¬ç ”ç©¶åœ¨GBMä¸­é‰´å®šäº†71ä¸ªä½ç”²åŸºåŒ–å¹¶é«˜æ°´å¹³è¡¨è¾¾çš„åŸºå› ï¼Œä»¥åŠ4ä¸ªé«˜ç”²åŸºåŒ–å¹¶ä½æ°´å¹³è¡¨è¾¾çš„åŸºå› ã€‚è¿™äº›åŸºå› ä¸»è¦å¯Œå«ä¸GBMå‘è‚²ç›¸å…³çš„â€œ JAK-STATä¿¡å·ä¼ å¯¼é€”å¾„â€ï¼Œâ€œç™Œç—‡è½¬å½•å¤±è°ƒâ€å’Œâ€œ ECM-å—ä½“ç›¸äº’ä½œç”¨â€ã€‚åœ¨ç¡®å®šçš„24ä¸ªä¸­å¿ƒåŸºå› ä¸­ï¼Œæœ‰15ä¸ªå…·æœ‰æ½œåœ¨çš„é¢„åä»·å€¼ã€‚ä¸ºäº†åˆ†æDNAç”²åŸºåŒ–ä¸åŸºå› è¡¨è¾¾å˜åŒ–ä¹‹é—´çš„å…³ç³»ï¼Œå¹¶è¯„ä¼°åŸºå› è¡¨è¾¾å˜åŒ–ä¸GBMç”Ÿå­˜æ—¶é—´çš„å…³ç³»ï¼Œå®æ–½äº†ä¸€ç§ç»¼åˆåˆ†ææ–¹æ³•ã€‚æœ¬ç ”ç©¶çš„ç»“æœè¡¨æ˜ï¼Œè¿™15ä¸ªåŸºäºCpGçš„åŸºå› å¯èƒ½æ˜¯é¢„æµ‹GBMæ‚£è€…é¢„åçš„æœ‰ç”¨å’Œå®ç”¨å·¥å…·ã€‚ç„¶è€Œï¼Œä¸ºäº†å¼€å‘é’ˆå¯¹GBMæ‚£è€…çš„ä¸ªæ€§åŒ–æ²»ç–—ï¼Œéœ€è¦å¯¹åŸºå› ç”²åŸºåŒ–å’Œ/æˆ–è¡¨è¾¾è¿›è¡Œè¿›ä¸€æ­¥çš„ç ”ç©¶ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724397[0m

Title: RNAseq profiling of circRNA expression in radiation-treated A549 cells and bioinformatics analysis of radiation-related circRNA-miRNA networks.

Journal: Oncology letters (Oncol Lett)

Date: 2020-Aug

Abstrct_EN: With the development of new biochemical and computational methods, circular RNAs (circRNAs) have been identified as microRNA sponges. circRNAs are associated with many diseases, particularly cancer. The present study aimed to investigate the expression profile of circRNAs in irradiated A549 lung cancer cells using high-throughput sequencing. Bioinformatics analyses were used to examine the potential functions of circRNAs. RNA sequencing data demonstrated that 1,875 circRNA targets were differentially expressed in A549 cells in response to irradiation. A total of 30 circRNAs were upregulated and 37 circRNAs were downregulated significantly in irradiation-treated A549 cells (fold change â‰¥2.0; P<0.05). The top 5 upregulated and downregulated circRNAs were successfully validated by reverse transcription-quantitative PCR. In addition, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis suggested that differentially expressed circRNAs might be pivotal in biological irradiation responses to irradiation. circRNA-microRNA co-expression networks highlighted the biological significance of circRNA_0002174 and circRNA_0036627, which require further study. In conclusion, the present study is, to the best of the authors' knowledge, the first to describe the differentially expressed profile of circRNAs in response to irradiation in A549 cells. These results provide a new perspective to elucidate insight into the molecular mechanisms by which A549 cells respond to radiation, and a basis for a more in-depth analysis of the potential application of circRNAs in the treatment of lung cancer therapy.

Abstrct_CN: éšç€æ–°çš„ç”ŸåŒ–å’Œè®¡ç®—æ–¹æ³•çš„å‘å±•ï¼Œç¯å½¢RNAï¼ˆcircRNAï¼‰å·²è¢«é‰´å®šä¸ºmicroRNAæµ·ç»µã€‚ circRNAä¸è®¸å¤šç–¾ç—…ï¼Œç‰¹åˆ«æ˜¯ç™Œç—‡æœ‰å…³ã€‚æœ¬ç ”ç©¶æ—¨åœ¨ä½¿ç”¨é«˜é€šé‡æµ‹åºç ”ç©¶circRNAåœ¨ç…§å°„çš„A549è‚ºç™Œç»†èƒä¸­çš„è¡¨è¾¾æƒ…å†µã€‚ç”Ÿç‰©ä¿¡æ¯å­¦åˆ†æç”¨äºæ£€æŸ¥circRNAçš„æ½œåœ¨åŠŸèƒ½ã€‚ RNAæµ‹åºæ•°æ®è¡¨æ˜ï¼Œå“åº”è¾å°„ï¼ŒA549ç»†èƒä¸­æœ‰1,875ä¸ªcircRNAé¶æ ‡å·®å¼‚è¡¨è¾¾ã€‚åœ¨ç»è¾å°„å¤„ç†çš„A549ç»†èƒä¸­ï¼Œæ€»å…±æœ‰30ä¸ªcircRNAä¸Šè°ƒï¼Œè€Œ37ä¸ªcircRNAæ˜¾ç€ä¸‹è°ƒï¼ˆå€æ•°å˜åŒ–â‰¥2.0ï¼› P <0.05ï¼‰ã€‚é€šè¿‡é€†è½¬å½•å®šé‡PCRæˆåŠŸéªŒè¯äº†å‰5ä¸ªä¸Šè°ƒå’Œä¸‹è°ƒçš„circRNAã€‚æ­¤å¤–ï¼ŒåŸºå› æœ¬ä½“è®ºï¼ˆGOï¼‰å’Œã€Šäº¬éƒ½åŸºå› ä¸åŸºå› ç»„ç™¾ç§‘å…¨ä¹¦ã€‹ï¼ˆKEGGï¼‰é€”å¾„åˆ†æè¡¨æ˜ï¼Œå·®å¼‚è¡¨è¾¾çš„circRNAå¯èƒ½åœ¨ç”Ÿç‰©è¾å°„å¯¹è¾å°„çš„ååº”ä¸­èµ·å…³é”®ä½œç”¨ã€‚ circRNA-microRNAå…±è¡¨è¾¾ç½‘ç»œçªæ˜¾äº†circRNA_0002174å’ŒcircRNA_0036627çš„ç”Ÿç‰©å­¦æ„ä¹‰ï¼Œéœ€è¦è¿›ä¸€æ­¥ç ”ç©¶ã€‚æ€»ä¹‹ï¼Œæ®ä½œè€…æ‰€çŸ¥ï¼Œæœ¬ç ”ç©¶æ˜¯ç¬¬ä¸€ä¸ªæè¿°circRNAsåœ¨A549ç»†èƒä¸­å¯¹æ”¾å°„ååº”çš„å·®å¼‚è¡¨è¾¾è°±çš„ç ”ç©¶ã€‚è¿™äº›ç»“æœä¸ºé˜æ˜A549ç»†èƒå¯¹æ”¾å°„ååº”çš„åˆ†å­æœºåˆ¶æä¾›äº†æ–°çš„è§è§£ï¼Œå¹¶ä¸ºæ›´æ·±å…¥åœ°åˆ†æcircRNAåœ¨è‚ºç™Œæ²»ç–—ä¸­çš„æ½œåœ¨åº”ç”¨å¥ å®šäº†åŸºç¡€ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724395[0m

Title: Overexpression of B7-H4 promotes renal cell carcinoma progression by recruiting tumor-associated neutrophils via upregulation of CXCL8.

Journal: Oncology letters (Oncol Lett)

Date: 2020-Aug

Abstrct_EN: The immune checkpoint molecule B7 family member H4 (B7-H4) plays a similar role to programmed death-ligand 1 in tumor immune evasion by regulating T-cell-mediated immune responses. However, besides the role in T-cell immunity, B7-H4 also affects tumor cell biology by promoting tumor cell proliferation, metastasis and angiogenesis. In order to explore the effect of B7-H4 on tumor cell biology, it is necessary to investigate the gene expression profile when B7-H4 is overexpressed. In the present study, 786-O cells were transfected to stably express B7-H4. A microarray technique was subsequently used to screen B7-H4-related differentially expressed genes (DEGs) in B7-H4/786-O cells compared with negative control (NC)/786-O cells. The protein expression of the upregulated DEGs, including non-metastatic cells 5, NME/NM23 family member 5 (NME5), membrane metalloendopeptidase (MME), vascular non-inflammatory molecule 1 (VNN1), matrix metalloproteinase (MMP) 7, tumor necrosis factor, C-X-C motif chemokine ligand (CXCL) 8, CXCL1 and C-C motif chemokine ligand (CCL) 2, was investigated using western blotting. Kidney renal papillary cell carcinoma mRNA-sequencing data obtained from The Cancer Genome Atlas revealed that chemokines, including CXCL1/2/3, CXCL8, MMP7 and CCL20, were positively correlated with B7-H4 gene expression. Furthermore, 59 clinical renal cell carcinoma tissues were collected and analyzed by immunohistochemical staining. The results revealed the positive correlation of B7-H4 with CCL20 and CXCL8, and validated the DEGs identified in tumor cell lines. 786-O transfectants were inoculated into non-obese diabetic/severe combined immunodeficiency mice, and tumor growth was investigated. B7-H4 overexpression promoted tumor growth and administration of anti-CXCL8 antibody reversed this effect. Furthermore, B7-H4 overexpression increased the number of tumor-infiltrating neutrophils while inhibition of CXCL8 abrogated this effect. These data indicated that recruitment of neutrophils in the tumor microenvironment by CXCL8 serves an important role in the tumor promotion effect of B7-H4. The present study revealed a novel mechanism of B7-H4 in tumor promotion in addition to T cell inhibition.

Abstrct_CN: å…ç–«æ£€æŸ¥ç‚¹åˆ†å­B7å®¶æ—æˆå‘˜H4ï¼ˆB7-H4ï¼‰é€šè¿‡è°ƒèŠ‚Tç»†èƒä»‹å¯¼çš„å…ç–«ååº”ï¼Œåœ¨è‚¿ç˜¤å…ç–«é€ƒé€¸ä¸­ä¸ç¨‹åºæ€§æ­»äº¡é…ä½“1å‘æŒ¥ç›¸ä¼¼çš„ä½œç”¨ã€‚ç„¶è€Œï¼Œé™¤äº†åœ¨Tç»†èƒå…ç–«ä¸­çš„ä½œç”¨å¤–ï¼ŒB7-H4è¿˜é€šè¿‡ä¿ƒè¿›è‚¿ç˜¤ç»†èƒå¢æ®–ï¼Œè½¬ç§»å’Œè¡€ç®¡ç”Ÿæˆæ¥å½±å“è‚¿ç˜¤ç»†èƒç”Ÿç‰©å­¦ã€‚ä¸ºäº†æ¢è®¨B7-H4å¯¹è‚¿ç˜¤ç»†èƒç”Ÿç‰©å­¦çš„å½±å“ï¼Œæœ‰å¿…è¦ç ”ç©¶B7-H4è¿‡è¡¨è¾¾æ—¶çš„åŸºå› è¡¨è¾¾è°±ã€‚åœ¨æœ¬ç ”ç©¶ä¸­ï¼Œè½¬æŸ“äº†786-Oç»†èƒä»¥ç¨³å®šè¡¨è¾¾B7-H4ã€‚ä¸é˜´æ€§å¯¹ç…§ï¼ˆNCï¼‰/ 786-Oç»†èƒç›¸æ¯”ï¼Œå¾®é˜µåˆ—æŠ€æœ¯éšåç”¨äºç­›é€‰B7-H4 / 786-Oç»†èƒä¸­B7-H4ç›¸å…³çš„å·®å¼‚è¡¨è¾¾åŸºå› ï¼ˆDEGï¼‰ã€‚ä¸Šè°ƒçš„DEGsçš„è›‹ç™½è¡¨è¾¾ï¼ŒåŒ…æ‹¬éè½¬ç§»ç»†èƒ5ï¼ŒNME / NM23å®¶æ—æˆå‘˜5ï¼ˆNME5ï¼‰ï¼Œè†œé‡‘å±å†…è‚½é…¶ï¼ˆMMEï¼‰ï¼Œè¡€ç®¡éç‚æ€§åˆ†å­1ï¼ˆVNN1ï¼‰ï¼ŒåŸºè´¨é‡‘å±è›‹ç™½é…¶ï¼ˆMMPï¼‰7ï¼Œè‚¿ç˜¤åæ­»ä½¿ç”¨è›‹ç™½è´¨å°è¿¹æ³•ç ”ç©¶äº†CXCåŸºåºè¶‹åŒ–å› å­é…ä½“ï¼ˆCXCLï¼‰8ï¼ŒCXCL1å’ŒCCåŸºåºè¶‹åŒ–å› å­é…ä½“ï¼ˆCCLï¼‰2è¿™ä¸€å› å­ã€‚ä»ç™Œç—‡åŸºå› ç»„å›¾è°±è·å¾—çš„è‚¾è„è‚¾ä¹³å¤´çŠ¶ç»†èƒç™ŒmRNAæµ‹åºæ•°æ®æ˜¾ç¤ºï¼ŒåŒ…æ‹¬CXCL1 / 2/3ï¼ŒCXCL8ï¼ŒMMP7å’ŒCCL20åœ¨å†…çš„è¶‹åŒ–å› å­ä¸B7-H4åŸºå› è¡¨è¾¾æ­£ç›¸å…³ã€‚æ­¤å¤–ï¼Œæ”¶é›†äº†59ä¸ªä¸´åºŠè‚¾ç»†èƒç™Œç»„ç»‡ï¼Œå¹¶é€šè¿‡å…ç–«ç»„ç»‡åŒ–å­¦æŸ“è‰²è¿›è¡Œäº†åˆ†æã€‚ç»“æœæ˜¾ç¤ºB7-H4ä¸CCL20å’ŒCXCL8å‘ˆæ­£ç›¸å…³ï¼Œå¹¶éªŒè¯äº†åœ¨è‚¿ç˜¤ç»†èƒç³»ä¸­é‰´å®šçš„DEGã€‚å°†786-Oè½¬æŸ“å­æ¥ç§åˆ°éè‚¥èƒ–å‹ç³–å°¿ç—…/ä¸¥é‡åˆå¹¶å…ç–«ç¼ºé™·å°é¼ ä¸­ï¼Œå¹¶ç ”ç©¶äº†è‚¿ç˜¤çš„ç”Ÿé•¿ã€‚ B7-H4è¿‡è¡¨è¾¾ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ï¼ŒæŠ—CXCL8æŠ—ä½“çš„ç»™è¯é€†è½¬äº†è¿™ä¸€æ•ˆåº”ã€‚æ­¤å¤–ï¼ŒB7-H4è¿‡è¡¨è¾¾å¢åŠ äº†è‚¿ç˜¤æµ¸æ¶¦ä¸­æ€§ç²’ç»†èƒçš„æ•°é‡ï¼Œè€Œå¯¹CXCL8çš„æŠ‘åˆ¶åˆ™åºŸé™¤äº†è¿™ç§ä½œç”¨ã€‚è¿™äº›æ•°æ®è¡¨æ˜CXCL8åœ¨è‚¿ç˜¤å¾®ç¯å¢ƒä¸­å‹Ÿé›†å—œä¸­æ€§ç²’ç»†èƒåœ¨B7-H4çš„è‚¿ç˜¤ä¿ƒè¿›ä½œç”¨ä¸­èµ·é‡è¦ä½œç”¨ã€‚æœ¬ç ”ç©¶æ­ç¤ºäº†B7-H4é™¤ä¿ƒè¿›Tç»†èƒå¤–è¿˜å…·æœ‰ä¿ƒè¿›è‚¿ç˜¤çš„æ–°æœºåˆ¶ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724376[0m

Title: MicroRNA-100 functions as a tumor suppressor in cervical cancer via downregulating the SATB1 expression and regulating AKT/mTOR signaling pathway and epithelial-to-mesenchymal transition.

Journal: Oncology letters (Oncol Lett)

Date: 2020-Aug

Abstrct_EN: Cervical cancer (CC) is a common malignant tumor among women worldwide, remaining the fourth most frequent cause of cancer death in women. Currently, microRNA (miRNA) is a prevalent topic in tumor-related research. The present study focused on the mechanisms of miR-100 in CC progression. qRT-PCR analysis revealed that the miR-100 expression was notably decreased in CC tissues. In addition, miR-100 downregulation was confirmed to be significantly related to the malignant clinicopathologic features of CC patients. Furthermore, miR-100 overexpression was also verified to significantly repress CC cell proliferation, migration and invasion abilities through modulating the AKT/mTOR signaling pathway and epithelial-to-mesenchymal transition. Bioinformatics analysis and luciferase reporter assay identified that special AT-rich sequence-binding protein 1 was a functional target for miR-100 in CC cells. Moreover, miR-100 overexpression was found to markedly repress the CC tumor growth <i>in vivo</i>. In conclusion, the above results revealed that miR-100 functioned as a cancer suppressor in CC progression and may provide insights into the novel therapeutic target for CC treatment.

Abstrct_CN: å®«é¢ˆç™Œï¼ˆCCï¼‰æ˜¯å…¨ä¸–ç•Œå¥³æ€§ä¸­å¸¸è§çš„æ¶æ€§è‚¿ç˜¤ï¼Œä»ç„¶æ˜¯å¥³æ€§æ­»äºç™Œç—‡çš„ç¬¬å››å¤§åŸå› ã€‚ç›®å‰ï¼ŒmicroRNAï¼ˆmiRNAï¼‰æ˜¯è‚¿ç˜¤ç›¸å…³ç ”ç©¶ä¸­çš„ä¸€ä¸ªæ™®éè¯é¢˜ã€‚æœ¬ç ”ç©¶é›†ä¸­äºmiR-100åœ¨CCè¿›å±•ä¸­çš„æœºåˆ¶ã€‚ qRT-PCRåˆ†ææ˜¾ç¤ºï¼ŒmiR-100è¡¨è¾¾åœ¨CCç»„ç»‡ä¸­æ˜æ˜¾é™ä½ã€‚æ­¤å¤–ï¼Œè¯å®miR-100ä¸‹è°ƒä¸CCæ‚£è€…çš„æ¶æ€§ä¸´åºŠç—…ç†ç‰¹å¾æ˜¾ç€ç›¸å…³ã€‚æ­¤å¤–ï¼Œè¿˜è¯å®äº†miR-100çš„è¿‡è¡¨è¾¾å¯é€šè¿‡è°ƒèŠ‚AKT / mTORä¿¡å·ä¼ å¯¼é€”å¾„å’Œä¸Šçš®-é—´è´¨è½¬åŒ–æ¥æ˜¾ç€æŠ‘åˆ¶CCç»†èƒå¢æ®–ï¼Œè¿ç§»å’Œä¾µè¢­èƒ½åŠ›ã€‚ç”Ÿç‰©ä¿¡æ¯å­¦åˆ†æå’Œè§å…‰ç´ é…¶æŠ¥å‘ŠåŸºå› åˆ†æé‰´å®šå‡ºï¼Œå¯Œå«ATçš„ç‰¹æ®Šåºåˆ—ç»“åˆè›‹ç™½1æ˜¯CCç»†èƒä¸­miR-100çš„åŠŸèƒ½é¶æ ‡ã€‚æ­¤å¤–ï¼Œå‘ç°miR-100è¿‡è¡¨è¾¾æ˜¾ç€æŠ‘åˆ¶ä½“å†…CCè‚¿ç˜¤çš„ç”Ÿé•¿ã€‚æ€»ä¹‹ï¼Œä»¥ä¸Šç»“æœè¡¨æ˜ï¼ŒmiR-100åœ¨CCè¿›å±•ä¸­èµ·ç™Œç—‡æŠ‘åˆ¶ä½œç”¨ï¼Œå¹¶å¯èƒ½ä¸ºCCæ²»ç–—çš„æ–°å‹æ²»ç–—é¶ç‚¹æä¾›è§è¯†ã€‚

[1m[33m####################################################################################################[0m

[1m[31mPubmed ID: 32724363[0m

Title: Increased frequency of <i>ESR1</i> mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor.

Journal: Oncology letters (Oncol Lett)

Date: 2020-Aug

Abstrct_EN: In several recent studies on metastatic breast cancer (MBC), ligand binding domain mutations of the estrogen receptor, which is coded by the <i>ESR1</i> gene, were induced by long-term endocrine therapy and resulted in acquired endocrine therapy resistance and poor outcomes. Knowledge of the association between the development of <i>ESR1</i> mutation and the clinicopathologic features may guide the decision-making process of metastatic breast cancer treatment, including endocrine therapy. The aim of the present study was to evaluate the association between the development of <i>ESR1</i> mutation and the clinicopathologic characteristics of patients with MBC. To evaluate the association between the development of <i>ESR1</i> mutation and clinicopathologic features, a cohort of 22 patients with MBC were retrospectively analyzed using next generation sequencing. In 14 of 22 patients, four mutations were detected on the metastatic site, including Tyr537Ser, Glu542Asp, Leu536Arg and Arg548Cys. Univariate analysis demonstrated that the duration of aromatase inhibitor and selective estrogen receptor modulator treatment, as well as the age of treatment initiation for early-stage breast cancer, were significantly associated with the development of <i>ESR1</i> mutation. <i>ESR1</i> mutation was identified in all five patients who received selective estrogen receptor modulators in the adjuvant setting followed by aromatase inhibitors in the metastatic setting, as well as in two of the three patients who received no selective estrogen receptor modulators in adjuvant setting followed by aromatase inhibitors in the metastatic setting. In conclusion, the results of the present study suggested that administrating adjuvant selective estrogen receptor modulator followed by aromatase inhibitor for metastasis may increase the frequency of <i>ESR1</i> mutation.

Abstrct_CN: åœ¨è¿‘æœŸå¯¹è½¬ç§»æ€§ä¹³è…ºç™Œï¼ˆMBCï¼‰çš„ä¸€äº›ç ”ç©¶ä¸­ï¼Œé•¿æœŸå†…åˆ†æ³Œæ²»ç–—è¯±å¯¼äº†<i> ESR1 </ i>åŸºå› ç¼–ç çš„é›Œæ¿€ç´ å—ä½“çš„é…ä½“ç»“åˆåŸŸçªå˜ï¼Œå¹¶å¯¼è‡´äº†è·å¾—æ€§å†…åˆ†æ³Œæ²»ç–—æŠµæŠ—åŠ›å’Œä¸è‰¯ç»“æœã€‚äº†è§£<i> ESR1 </ i>çªå˜çš„å‘å±•ä¸ä¸´åºŠç—…ç†ç‰¹å¾ä¹‹é—´çš„å…³è”å¯èƒ½ä¼šæŒ‡å¯¼è½¬ç§»æ€§ä¹³è…ºç™Œæ²»ç–—ï¼ˆåŒ…æ‹¬å†…åˆ†æ³Œæ²»ç–—ï¼‰çš„å†³ç­–è¿‡ç¨‹ã€‚æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯è¯„ä¼°<i> ESR1 </ i>çªå˜çš„å‘å±•ä¸MBCæ‚£è€…ä¸´åºŠç—…ç†ç‰¹å¾ä¹‹é—´çš„å…³ç³»ã€‚ä¸ºäº†è¯„ä¼°<i> ESR1 </ i>çªå˜çš„å‘å±•ä¸ä¸´åºŠç—…ç†ç‰¹å¾ä¹‹é—´çš„å…³ç³»ï¼Œé‡‡ç”¨ä¸‹ä¸€ä»£æµ‹åºæ–¹æ³•å¯¹22ä¾‹MBCæ‚£è€…è¿›è¡Œå›é¡¾æ€§åˆ†æã€‚åœ¨22ä¾‹æ‚£è€…ä¸­çš„14ä¾‹ä¸­ï¼Œåœ¨è½¬ç§»éƒ¨ä½æ£€æµ‹åˆ°å››ä¸ªçªå˜ï¼ŒåŒ…æ‹¬Tyr537Serï¼ŒGlu542Aspï¼ŒLeu536Argå’ŒArg548Cysã€‚å•å› ç´ åˆ†æè¡¨æ˜ï¼ŒèŠ³é¦™é…¶æŠ‘åˆ¶å‰‚å’Œé€‰æ‹©æ€§é›Œæ¿€ç´ å—ä½“è°ƒèŠ‚å‰‚çš„æ²»ç–—æ—¶é—´ä»¥åŠæ—©æœŸä¹³è…ºç™Œçš„æ²»ç–—èµ·å§‹å¹´é¾„ä¸<i> ESR1 </ i>çªå˜çš„å‘ç”Ÿå¯†åˆ‡ç›¸å…³ã€‚åœ¨è¾…åŠ©æ²»ç–—ä¸­æ¥å—é€‰æ‹©æ€§é›Œæ¿€ç´ å—ä½“è°ƒèŠ‚å‰‚ï¼Œéšååœ¨è½¬ç§»æ€§æ²»ç–—ä¸­æ¥å—èŠ³é¦™é…¶æŠ‘åˆ¶å‰‚çš„æ‰€æœ‰äº”åæ‚£è€…ä¸­ä»¥åŠæ‰€æœ‰æœªæ¥å—é€‰æ‹©æ€§é›Œæ¿€ç´ å—ä½“è°ƒèŠ‚å‰‚çš„ä¸‰åæ‚£è€…ä¸­çš„ä¸¤åä¸­é‰´å®šå‡ºäº†<i> ESR1 </ i>çªå˜åœ¨ä½å‰‚ç¯å¢ƒä¸­ï¼Œå…¶æ¬¡æ˜¯èŠ³é¦™é…¶æŠ‘åˆ¶å‰‚ï¼Œåœ¨è½¬ç§»ç¯å¢ƒä¸­ã€‚æ€»ä¹‹ï¼Œæœ¬ç ”ç©¶çš„ç»“æœè¡¨æ˜ï¼Œåœ¨è½¬ç§»åç»™äºˆä½å‰‚é€‰æ‹©æ€§é›Œæ¿€ç´ å—ä½“è°ƒèŠ‚å‰‚å’ŒèŠ³é¦™é…¶æŠ‘åˆ¶å‰‚å¯èƒ½ä¼šå¢åŠ <i> ESR1 </ i>çªå˜çš„é¢‘ç‡ã€‚

[1m[33m####################################################################################################[0m

